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Thoracic aortic aneurysms and dissections (TAAD) are the primary disease
affecting the thoracic ascending aorta, with an incidence rate of 10.4/100,000. Although
about 20% of patients carry a mutation in a single gene that causes their disease, the
remaining 80% of patients may also have genetic factors that increase their risk for
developing TAAD. Many of the genes that predispose to TAAD encode proteins
involved in smooth muscle cell (SMC) contraction and the disease-causing mutations are
predicted to disrupt contractile function. SMCs are the predominant cell type in the
ascending aortic wall. Mutations in MYH11, encoding the smooth muscle specific
myosin heavy chain, are a rare cause of inherited TAAD. However, rare but recurrent
non-synonymous variants in MYH11 are present in the general population but do not
cause inherited TAAD. The goal of this study was to assess the potential role of these
rare variants in vascular diseases. Two distinct variants were selected: the most
commonly seen rare variant, MYH11 R247C, and a duplication of the chromosomal
region spanning the MYH11 locus at 16p13.1. Genetic analyses indicated that both of
these variants were significantly enriched in patients with TAAD compared with
controls.
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A knock-in mouse model of the Myh11 R247C rare variant was generated, and
these mice survive and reproduce normally. They have no structural abnormalities of the
aorta or signs of aortic disease, but do have decreased aortic contractility.
Myh11R247C/R247C mice also have increased proliferative response to vascular injury in
vivo and increased proliferation of SMCs in vitro. Myh11R247C/R247C SMCs have
decreased contractile gene and protein expression and are dedifferentiated. In fibroblasts,
myosin force generation is required for maturation of focal adhesions, and enhancers of
RhoA activity replace enhancers of Rac1 activity as maturation occurs. Consistent with
these previous findings, focal adhesions are smaller in Myh11R247C/R247C SMCs, and there
is decreased RhoA activation. A RhoA activator (CN03) rescues the dedifferentiated
phenotype of Myh11R247C/R247C SMCs.
Myh11R247C/R247C mice were bred with an existing murine model of aneurysm
formation, the Acta2-/- mouse. Over time, mice carrying the R247C allele in conjunction
with heterozygous or homozygous loss of Acta2 had significantly increased aortic
diameter, and a more rapid accumulation of pathologic markers. These results suggest
that the Myh11 R247C rare variant acts as a modifier gene increasing the risk for and
severity of TAAD in mice.
In patients with 16p13.1 duplications, aortic MYH11 expression is increased, but
there is no corresponding increase in smooth muscle myosin heavy chain protein. Using
SMCs that overexpress Myh11, we identified alterations in SMC phenotype leading to
excessive protein turnover. All contractile proteins, not just myosin, are affected, and the
proteins are turned over by autophagic degradation. Surprisingly, these cells are also
more contractile compared with wild-type SMCs.

vi

The results described in this dissertation firmly establish that rare variants in
MYH11 significantly affect the phenotype of SMCs. Further, the data suggests that these
rare variants do increase the risk of TAAD via pathways involving altered SMC
phenotype and contraction. Therefore, this study validates that these rare genetic variants
alter vascular SMCs and provides model systems to explore the contribution of rare
variants to disease.
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Chapter 1: Introduction

1

The Aorta
The aorta is the largest blood vessel in the body, and it carries blood directly
from the left ventricle of the heart to feed the rest of the body. Like other vessels, there
are three distinct layers of the aorta: the tunica intima, tunica media, and tunica
adventitia [1,2]. A single cell layer of endothelial cells lining the vessel lumen forms the
intimal layer of the vessel. The intimal layer acts as a barrier between the luminal blood
and the vessel wall. The adventitial layer, on the external side of the vessel, is comprised
of extracellular matrix collagens, fibroblasts, progenitor cells, and, in the case of the
aorta, the vasa vasorum or “vessels of the vessels” which feed blood to the external
portion of the aortic wall [3]. Most important for vascular function is the medial layer,
which in the aorta and other elastic arteries consists of concentric layers of smooth
muscle cells (SMCs) separated by rings of elastin fibers (Figure 1.1A) [1,2,4]. In
smaller, “muscular” arteries, there are only two elastin rings at the borders separating the

Figure 1.1 Arterial structure. A) Movat pentachrome stain of normal human aorta
showing the aortic media comprised of concentric layers of smooth muscle cells (red)
interspersed with elastic fibers (black). B) Movat pentachrome stain of human
muscluar artery from the vasa vasorum. Black arrows indicate internal elastic lamina,
white arrows indicate external elastic lamina. Reprinted with permission from
Genetics in Medicine [Genetic variants promoting smooth muscle cell proliferation
can result in diffuse and diverse vascular diseases: Evidence for a hyperplastic
vasculomyopathy. Milewicz DM, Kwartler CS, Papke CL, Regalado E, Cao J, Reid A.
2010.]
2

media from the intima and the adventitia (Figure 1.1B). In all vessels, elastic or
muscular, the elastin ring separating the intimal and medial layers is termed the internal
elastic lamina and the elastin ring separating the adventitial and medial layers is termed
the external elastic lamina [2,4].
Elastin rings are laid down during development; no additional layers are added
during adulthood in response to biomechanical forces or injury. The number of elastic
lamellae is fixed and highly regulated for each portion of the vessel wall and each
organism [4,5]. Increased numbers of elastin layers increase the tensile force that can be

Figure 1.2 Elastin-contractile unit. Illustration shows the lamellar unit of the
aortic wall, with linear connections between the smooth muscle cell contractile
units and the elastic fibers formed by microfibrils. Reprinted with permission
Elsevier Books [MuscleFundamental Biology and Mechanisms of Disease,
Volume 2 , Chapter 97 “Genetic Variants in Smooth Muscle Contraction and
Adhesion Genes Cause Thoracic Aortic Aneurysms and Dissections and Other
Vascular Diseases”. Milewicz DM, Kwartler CS.]
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generated by the vessel walls, so generally vessels that experience increased pulsatile
pressures, like the thoracic ascending aorta, have the highest numbers of elastic layers
[6,7].
In the aortic wall, individual layers of SMCs surrounded by two elastin rings are
termed “lamellar units” (Figure1.2). The elastin fibers connect to the SMCs via
microfibrils, composed predominantly of fibrillin-1 with other supporting extracellular
matrix proteins like fibronectin [1,8]. Contact between the microfibrils and the cell body
occurs at points on the cell surface known as dense plaques, also known as focal
adhesions in single layered cell cultures. Dense plaques or focal adhesions are large and
dynamic protein complexes that directly link with the contractile apparatus within the
SMC. Thin filaments, comprised of smooth muscle specific α-actin, slide against thick
filaments, whose backbone is formed by smooth muscle specific β-myosin heavy chain,
to make up the contractile unit in SMCs. Additional adaptor proteins, like calponin,
tropomyosin, and smoothelin, stabilize the structure and enhance the function of the
contractile unit.

Smooth muscle contractile function
Like all muscle cells, SMCs depend on the motor function of myosin to drive
contraction [9]. Filaments of myosin contain units of 6-protein complexes: two heavy
chains, two regulatory light chains, and two essential light chains. Each myosin heavy
chain has a globular head domain that contains actin-binding and ATP-binding sites, a
linker domain which contains the sites of light chain binding, and a coiled-coil domain
which enables interaction with other myosin heavy chain monomers to form first dimers,
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then filamentous multimers (Figure 1.3). SMCs do not have a rigidly structured
sarcomere like cardiac and skeletal muscle cells, but rather have dynamic contractile
filaments arranged in a lattice-like structure spanning the cell body [10].

Figure 1.3 Myosin monomer ultrastructure. Illustration shows overall structure of
the myosin molecule with a globular catalytic head domain, a lever arm where binding
of light chain occurs, and a coiled coil domain for filament formation. Figure prepared
by H. Lee Sweeney, Ph.D. and reprinted with permission.
Some studies suggest that the myosin thick filaments in SMCs actually form in
response to contractile stimuli [11]. Although there are some stable filaments within the
resting SMC, stimulation of contraction drives the number of thick filaments to increase,
suggesting that monomeric pools of myosin may exist in a relaxed SMC [11,12].
Phosphorylation of the myosin regulatory light chain (RLC) is responsible for both the
formation of thick filaments and also the activation of filamentous myosin through
activating cross-bridges with actin in thin filaments [13]. The phosphorylation of the
RLC is controlled by a specific kinase, myosin light chain kinase (MLCK), and a
phosphatase (Figure 1.4). MLCK is primarily activated by increased intracellular
calcium ion concentration and binding of calcium ions to calmodulin. The calciumcalmodulin complex dramatically upregulates the activity of MLCK to phosphorylate
RLC at serine 19 [14]. Adrenergic receptor stimulation leads to release of calcium ions
from the sarcoplasmic reticulum, which in turn activates a number of ion channels on the
cell surface, magnifying the ionic excitation within the cell [15]. After stimulation ends,
5

Figure 1.4 Schematic of signaling events leading to SMC contraction. Illustration
shows signaling events in vascular SMCs leading to contraction. The key event driving
contraction is phosphorylation of the myosin light chain. Figure prepared by James T.
Stull, Ph.D., and Kristine Kamm, Ph.D.,. and reprinted with permission.
loss of intracellular calcium leads to a decrease in MLCK activity, and the myosin light
chain phosphatase is able to de-phosphorylate RLC. The phosphatase is a protein
complex comprised of three units: a catalytic unit (PP1C), a targeting subunit (MYPT),
and a protein of unknown function (M20); its activity can be modulated by a variety of
cellular signaling events, including activation of Rho-associated protein kinase (ROCK)
or phospho-lipase C γ, which lead to downregulation of phosphatase activity and
sensitizes the SMC to pro-contractile stimuli [16,17].
Myosin is by definition an actin-activated ATPase, with a nucleotide binding
pocket and catalytic activity allowing the hydrolysis of ATP into ADP + Pi. There are
three major globular domains of the head, of which one (the 50kD domain) is split by a
6

large cleft known as the 50kD cleft. The two sides of the cleft are separated by a loop
known as “switch II.” Actin binds to a series of loops on the external surface of both the
upper 50kD domain and the lower 50kD domain. Nucleotide binding occurs near the
switch II loop at the joint of the two halves of the 50kD domain. Two flexible linkers, a
relay loop and the SH1 helix connect the 50kD domain to the converter domain, which is
adjacent to the lever arm (Figure 1.5) [18,19].

Figure 1.5 Myosin head domain structure. Illustration shows subdomains within the
myosin head domain that are crucial for motor function. Actin binds between the upper
50K domain and the lower 50K domain. Figure prepared by H. Lee Sweeney, Ph.D. and
reprinted with permission.
The myosin kinetic cycle involves a number of conformational rearrangements of
the subdomains of the head (Figure 1.6). In the prepowerstroke structure, the 50kD cleft
is partially closed at the site of nucleotide binding [20]. Actin is either unbound or
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Figure 1.6 Actin-Myosin kinetic cycle. Illustration of the basic steps in the actinmyosin kinetic cycle.
weakly bound, and as ATP is hydrolyzed the gamma phosphate is trapped at the binding
site [21]. This leads to full closure of the cleft, allowing all the actin-binding loops to be
brought together for strong actin binding, and the “back door” of switch II opens to
release the phosphate group [22]. These relatively small motions in the 50kD domain
are transduced through the converter domain and the lever arm swings around to provide
the full range of force-generating motion of the powerstroke [23]. After the stroke, the
molecule is in a rigor-like state where the cleft is completely closed. The cycle is
completed when ADP is released, ATP is rebound, actin dissociates from myosin, and
the lever arm is reprimed for the next stroke.
Within the vessel wall, SMC contraction is regulated by blood flow from the
heart and autonomic nervous cues, like the release of contractile agonist epinephrine.
However, elastic fibers produce the majority of the tensile force within the aortic wall,
and the role of SMCs in vascular contractility is debated [7]. In one study, vascular rings

8

Figure 1.7 Isoforms of smooth muscle myosin heavy chain. Illustration shows the four
isoforms of smooth muscle myosin heavy chain encoded by MYH11. –A and –B differ from
each other by inclusion of a seven amino acid insertion in the head domain. -1 and -2 harbor
distinct c-terminal exons. Reprinted with permission from John Wiley and Sons [Smooth
muscle myosin heavy chain isoforms and their role in muscle physiology. Babu GJ, Warshaw
DM, Periasamy M. Microscopy Research and Technique. 2000].
were subjected to pressure, and contractility was measured, both before and after
administration of a substance that killed the SMCs. Both measurements revealed the
same distensibility and contractile force generation, suggesting that the cells do not
contribute to the mechanical properties of the vessel [24]. Other studies have alternately
shown a role for SMC contraction in large arteries during acclimation to increased
biomechanical forces [25,26]. Currently, consensus in the field suggests that SMCs act
as biomechanical sensors in small arteries, responding to stimuli and regulating
contraction in response to changes in pressure, but the role of SMCs in large, elastic
arteries has not been determined.

9

Smooth muscle myosin isoforms and contractile function
The gene encoding smooth muscle myosin heavy chain (MYH11) actually
encodes four separate mRNA transcripts which are translated into distinct isoforms of
myosin heavy chain. The four isoforms are designated as SM1A, SM2A, SM1B, and
SM2B; the designation of A vs. B is determined by the presence (B) or absence (A) of a
seven amino acid insertion within the myosin head region, while the designation of 1 vs.
2 is determined by inclusion of distinct N-terminal exons (Figure 1.7). SM-B isoforms
are predominantly expressed in the bladder and intestines; although some SM-B
expression is observed in smaller arteries it is absent from the mature aorta [27]. In mice,
knockout of the SM-B isoforms results in decreased shortening velocity but increased
force generation in the smaller arteries and significantly reduced force generation in the
bladder [28].
SM1A and SM2A are each expressed highly within the aorta, though vascular
injury or atherosclerotic remodeling results in a decrease in specific expression of SM2A
[29,30]. In vitro studies show that SM2 myosin has a higher critical concentration for
filament assembly than SM1 myosin [31]. Specific knockout of the SM2 isoforms
similarly resulted in increased contractile responses to stimuli, and additionally caused
lethality by 4 weeks of age due to multiorgan failure [32]. These results suggest the
importance of regulating smooth muscle contractile function in maintaining a healthy
and viable mouse. Furthermore, transgenic overexpression of either SM1A or SM2A
lead to dramatically different physiologic changes: SM1A overexpression increases
force generation in both the aorta and bladder smooth muscle, whereas SM2A
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overexpression decreases force generation in both tissues [33]. However, in both
transgenic models, the ratio of expression of SM1 to SM2 was unaltered by specific
overexpression of one isoform [33]. The latter strongly suggests that myosin isoform
ratios are tightly controlled within each tissue, and that very small changes in those
isoform ratios may result in highly significant changes in the contractile properties of the
muscle tissue.

Smooth muscle cell phenotypic plasticity
Smooth muscle cells, unlike cardiac or skeletal muscle cells, retain phenotypic
plasticity even in the mature vessel. Quiescent SMCs, such as those that populate the

Figure 1.8 Smooth muscle cell phenotypic switching. Illustration shows two
distinct phenotypes of vascular smooth muscle cells: on the left, the synthetic cell
and on the right the contractile cell. Reprinted with permission from Genetics in
Medicine [Genetic variants promoting smooth muscle cell proliferation can result in
diffuse and diverse vascular diseases: Evidence for a hyperplastic vasculomyopathy.
Milewicz DM, Kwartler CS, Papke CL, Regalado E, Cao J, Reid A. 2010.]
11

healthy aortic wall, are spindle shaped, do not proliferate or migrate, and express high
levels of contractile proteins [34]. In these cells, the contractile proteins are assembled
into the lattice-like filament structures; this phenotype is therefore termed “contractile.”
However, in response to stimuli such as injury, growth factor signaling, or changes in
mechanical force, SMCs can switch from expression of contractile genes to expression
of growth-related and extracellular matrix-related genes [35]. The contractile filaments
disassemble, and the cells proliferate, migrate, and secrete large quantities of matrix
proteins to help repopulate damaged areas of the vessel wall or improve the strength of
the wall in response to increased biomechanical pressures (Figure 1.8).
The dogma in SMC biology holds that SMCs can take on either a “contractile” or
a “proliferative” phenotype, which are mutually exclusive. A canonical pathway, known
as the serum response factor (SRF): myocardin related transcription factor (MRTF) axis,
is thought to control the switch between the two phenotypes [36]. SRF is a promiscuous,
and ubiquitously expressed, transcription factor, which can drive transcription of over
200 genes, and specificity for particular target genes is conferred via the binding of
transcriptional coactivators [34,37,38]. Three members of the MRTF family of
coactivators are specifically expressed in cardiomyocytes and SMCs: myocardin,
MRTF-A, and MRTF-B [39]. Myocardin, which is constitutively localized to the
nucleus, plays a key role in cardiac development; knockout of the Myocd gene leads to
embryonic lethality at E10.5 due to heart and vascular development defects [40]. MRTFA and –B, however, can move within the cell between the nucleus and the cytoplasm,
and are predominantly expressed in SMCs [38,41]. Within the cytoplasm, monomeric or
G-actin can bind to MRTFs, so as the contractile filaments disassemble in response to

12

growth factor or mechanical signals, MRTFs become sequestered in the cytoplasm. SRF
is thus available to bind other coactivators, such as ternary complex factor (TCF), and
drive expression of growth-related genes [38,39]. Differentiation of SMCs is
accompanied by actin polymerization, as driven by the small G-protein RhoA. As actin
polymerizes, MRTFs are free to move back into the nucleus, where they bind SRF and
drive transcription of contractile genes [42].

Thoracic aortic aneurysms and dissections
Aortic aneurysms and dissections have an incidence of 10.4/100,000, and result
in approximately 15,000 deaths per year [43]. An aneurysm is an enlargement of the
vessel wall, and the natural history of thoracic aortic aneurysms is to progress to a

Figure 1.9 Thoracic aortic aneurysms and dissections. Illustration of ascending aortic
aneurysm (left) and the Stanford classification of aortic dissection (right). Yellow
indicates the site of the tear in the wall: the ascending aorta for a type A dissection vs the
descending aorta for a type B dissection.
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dissection, or tear in the wall, if the aneurysm is not surgically repaired [44,45].
Dissections are medical emergencies requiring immediate surgery; approximately one
third of dissection cases die suddenly and the death rate in survivors of aortic dissections
is 1% per hour until surgery is performed [45,46]. Thoracic aortic aneurysms and
dissections, collectively termed “TAAD,” are classified by their location within the
aorta. The Stanford classification system for aortic dissections classifies any tear
originating in the ascending aorta as “Type A” while any tear originating in the
descending aorta or arch is “Type B” (Figure 1.9) [43,47].
While aneurysms are typically asymptomatic, aortic dissections can cause severe
chest pain, in conjunction with sudden changes in blood pressure, dyspnea, sweating,
and a feeling of faintness or numbness [44]. Approximately 30 - 40% of patients with
acute aortic dissections die before reaching the emergency room [45,46]. For those who
do, the clinical presentation is similar to myocardial infarction, making this significantly
less common disease difficult to diagnose. Any delay in diagnosis, however, increases
the risk of death as the patients’ vascular function declines and the risk of complete
aortic rupture increases. Standard diagnostic imaging to detect aortic dissection includes
computed tomography (CT) scan and transesophageal echocardiography [45,46].
Surgical repair of the injured artery is the only available recourse for patients with acute
dissections, but many patients do not survive the procedure.
Alternatively, if an aneurysm is detected prior to dissections, prophylactic repair
can be performed when the aneurysms reaches approximately twice the normal diameter
of the aorta [43]. This strategy greatly increases survival, so medical efforts should be
focused on identifying patients at risk for TAAD, monitoring the patients, and
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recommending surgery once the aortic diameter exceeds a threshold size correlated with
the body size of the patient.
Pathologic examination of aortic tissue from TAAD patients reveals a
characteristic set of changes in the diseased aorta (Figure 1.10). Fragmentation or loss of
the elastic fibers in the aortic media is commonly observed, together with focal loss or
accumulation of medial SMCs. Additionally, the composition of the extracellular matrix
changes, with proteoglycans accumulating and filling in the spaces left by absent cells
and elastin fibers. Together, these pathologic changes were previously known as “cystic
medial degeneration” but are currently termed medial degeneration [1,4,48].

Figure 1.10 Medial degeneration. Representative pathologic sections showing a
normal human aorta on the left and an aneurysmal specimen with the classic pathology
of medial degeneration on the right. Sections are stained with MOVAT pentachrome
stain: black is elastin fibers, blue is proteoglycans, red is smooth muscle cells.
Fragmentation of the elastin fibers may be accomplished by an increase in the
activity of matrix metalloproteinases (MMPs), which are Zn-dependent proteases that
cleave multiple target proteins within the extracellular matrix [49,50]. Elastin is a known
inhibitor of SMC proliferation, so when the elastin becomes fragmented, focal SMC

15

proliferation can occur. In other spaces within the wall, apoptotic death of SMCs leads to
focal areas of cellular loss. The role of inflammation in the progression of TAAD is not
well characterized, but evidence of macrophage accumulation is apparent in a subset of
patients, particularly at the end stages of the disease [1,4].

Genetic basis of TAAD
There is a strong genetic component to the pathogenesis of TAAD. First, TAAD
is a feature of a number of inherited syndromes, the best characterized of which is
Marfan syndrome (MFS). Less than 5% of patients with TAAD have one of these
genetic syndromes. An additional 15% of patients indicate a family history of the disease
in the absence of syndromic features. These patients are classified as having “familial
TAAD” or fTAAD, and their family members in turn are at high risk for the disease
[45,51]. The remaining 80% of patients have no known genetic history of the disease,
and are classified as “sporadic” or sTAAD. All genes identified to date for either
syndromic or familial TAAD are inherited in an autosomal dominant manner. The
natural history of the disease in any given patient or family is dependent upon the
underlying mutation: some mutations lead to the formation of large stable aneurysms,
while others can lead to dissection and rupture with minimal prior enlargement [52].
Thus, identifying mutations can help to dictate the preferred course of treatment for
patients with this disease.
MFS is a connective tissue disorder which leads to abnormalities in the skeletal,
ocular, pulmonary, and cardiovascular systems [53]. The gene mutated in MFS patients
was identified in 1991 as FBN1, encoding the extracellular matrix protein fibrillin-1. As
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described above, in the aorta fibrillin-1 is the major component of the microfibrils that
connect SMCs with the elastin fibers. In addition to its important structural role, fibrillin1 also plays a signaling role in the aortic wall by sequestering latent growth factors, in
particular transforming growth factor β (TGF-β) [1,53]. Mutations in FBN1 are proposed
to induce excessive TGF-β signaling by inhibiting its sequestration in the matrix, and
this excessive signaling is believed to underlie the pathogenesis of TAAD in MFS
patients [54].
A role for dysregulated TGF-β signaling in TAAD is further supported by
multiple mutations within the TGF-β signaling pathway itself that in some cases also
cause a syndromic presentation. Mutations in TGFBR1 and TGFBR2, encoding the two
cell-surface receptors for the TGF-β ligand, underlie Loeys-Dietz Syndrome (LDS),
which involves craniofacial dysmorphia, atrophic scarring, bifid uvula, and arterial
tortuosity in addition to TAAD at a very young age [55,56]. Mutations in SMAD3, one
of the canonical intracellular signaling molecules downstream of TGF-β, cause a
presentation of TAAD in conjunction with osteoarthritis [57]. Finally, mutations in
TGFB2, encoding one of the three TGF-β ligands, cause TAAD in conjunction with mild
MFS-like features [58]. Mutations in all four genes can additionally cause fTAAD
without significant syndromic features, suggesting that the classification of TAAD lies
on a spectrum rather than three distinct and mutually exclusive presentations.
In addition to mutations in genes encoding proteins involved in TGF-β signaling,
a second cluster of mutations has been identified leading to TAAD: mutations in genes
encoding SMC-specific contractile proteins. The most commonly mutated gene in
families with fTAAD is ACTA2, encoding the SMC-specific isoform of α-actin [59].
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Additionally, mutations in MYH11 encoding the SMC-specific myosin heavy chain, and
in MLCK encoding the kinase which regulates myosin contractility, have been identified
[60,61]. Furthermore, families with mutations in MYH11 are also predisposed to a
developmental disease known as patent ductus arteriosus (PDA) in which the fetal
connection between the aorta and the pulmonary artery fails to close [61].
Surprisingly, studies of a large ACTA2 family indicated that only 50% of
mutation carriers developed TAAD; however, in addition to TAAD the mutation carriers
in the family were also at high risk of early-onset vascular occlusive diseases like strokes
or coronary artery disease [62]. Further studies of additional families confirmed that
ACTA2 mutations lead to both aneurysmal and occlusive vascular diseases. One
particularly severe mutation, R179H, has been identified in a number of children with a
syndrome-like presentation of global SMC dysfunction: primary pulmonary
hypertension, hypoperistalsis in the gut, bladder dysfunction, and both aortic and
cerebrovascular disease [63].
Intriguingly, pathologic examination of the occlusive vascular lesions in these
patients reveals an absence of typical atherosclerotic features: the lesions are fibrin,
calcium, and lipid poor. Instead, the occlusion appears to occur due solely to hyperplasia
of SMCs, as the lesion is exclusively full of proliferating cells that stain positively for
SMC markers [2]. These findings suggest that a single mutation can lead to a diverse
array of vascular diseases, and that alteration of SMC phenotype towards a more
proliferative phenotype may underlie some of the increased risk for vascular occlusive
diseases.
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TGF-β Signaling and TAAD
As described above, mutations of several components of the TGF-β signaling
pathway have been associated with TAAD. The majority of these mutations are
predicted to be loss-of-function [64]. However, other studies have reported a paradoxical
increase in TGF-β signaling markers in late-stage disease tissue from TAAD patients
harboring these mutations [54,58]. Thus, the specific role of TGF-β in driving aneurysm
progression remains controversial.
The TGF-β superfamily of growth factors includes three distinct transforming
growth factor β ligands. These three ligands each bind to a heterodimer of the two
transforming growth factor β receptors (TGFBR1 and TGFBR2), which are receptor
tyrosine kinases that phosphorylate each other as well as downstream targets in response
to ligand binding. The canonical pathway downstream of the TGF-β receptors involves a
family of molecules known as Smads; in response to TGF-β ligand binding to the
receptors, Smad2 and Smad3, the receptor-regulated or R-Smads for TGF-β receptors,
are activated. These two R-Smads can then bind to the co-Smad, Smad4, and translocate
to the nucleus where they activate a program of signal transduction. In addition to the
canonical Smad pathway, the TGF-β receptors can also activate non-canonical pathways
leading to activation of mitogen-associated protein kinase (MAPK) signaling and other
pathways [65].
TGF-β signaling produces a number of short- and long-term effects in SMCs.
Many transcriptional targets of TGF-β signaling are extracellular matrix proteins, in
particular collagens, which drive a process known as fibrosis. Transcription of
extracellular matrix proteins is associated with the proliferative and synthetic phenotype
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of SMCs that occurs post vascular injury. However, TGF-β signaling also drives
differentiation of SMCs by inducing transcription of contractile genes including ACTA2
and MYH11 [66]. Extensive studies of SMCs from patients with mutations in TGFBR1
or TGFBR2 indicate that these SMCs are unable to differentiate properly. The cells are
characterized by poor expression of contractile markers in conjunction with reduced
proliferation and expression of collagen genes [64]. Interestingly, TGF-β signaling can
activate both canonical Smad signaling and noncanonical signaling via MAPKs. Smad
signaling is intact in TGFBR2 cells, but non-canonical signaling through p38MAPK and
Akt are blunted [64,67]. These studies clearly indicate a loss of function due to
mutations in TGFBR1 or TGFBR2, however increased phosphorylated Smads, indicative
of increased TGF-β signaling, persist in the tissue.
A similar paradox occurs in patients with TGFB2 mutations: the cells isolated
from these patients show a decrease in TGFB2 gene expression and TGF-β2 protein
accumulation, but in the diseased tissue both gene expression and protein accumulation
are increased [58]. These confusing results suggest that, although these mutations are
loss-of-function, at some point in the disease process signaling is turned on to a
pathologically high level. However, the exact role of this excessive TGF-β signaling in
driving the disease has yet to be established.

Smooth muscle cell dysfunction in TAAD
As genetic mutations in SMC-specific contractile proteins also cause TAAD, an
alternative hypothesis regarding the underlying pathogenesis of the disease involves loss
of SMC contractility and function. This hypothesis is intriguing, as mutations in the
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TGF-β pathway may also lead to a loss of SMC contractility by impairing differentiation
of SMCs as described above. Initial studies on SMCs isolated from ACTA2 and MYH11
patients support this hypothesis, as these cells completely lack the α-actin filaments that
stretch across the entirety of wild-type cells (Figure 1.11) [59,68]. If contractile
filaments do not form, contractile function in these cells must necessarily be impaired.
Although, as described above, there is some debate as to the role of SMC contraction in
regulating the mechanical properties of the aorta as a whole, if the SMCs are not able to
contract the cells themselves will sense increased, unopposed tension. The cells may
attempt to normalize the biomechanical stress by activating signaling pathways, and
these signaling pathways, which might include excessive activation of TGF-β, may drive
the disease process.
Mutations in ACTA2 and MYH11 at least have been correlated with occlusive
vascular lesions characterized by hyperplastic SMCs. Our lab has performed a number of
studies to confirm that cells harboring mutations in these genes do, in fact, proliferate
more rapidly both in culture and in vivo [62]. The role of this cellular hyperplasia in
driving occlusive disease seems obvious; however, it is unknown whether proliferation
of SMCs contributes to aortic aneurysm development.
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Figure 1.11 Contractile dysfunction in familial TAAD. Immunofluorescent staining of
SMCs explanted from controls (top row) shows colocalization of SM-actin staining
(green) with phalloidin (red) indicating polymerized SM-actin. SMCs explanted from
fTAAD patients with mutations in three different proteins show a loss of polymerized
SM-actin. Counterstained with DAPI (blue).
The pathways driving SMC hyperplasia in patients with mutations in ACTA2 and
MYH11, however, are less clear. Recent work in our lab has used SMCs completely
lacking α-actin from the Acta2-/- mouse model to elucidate these pathways. Surprisingly,
in these cells the canonical SRF:MRTF axis does not drive hyperplasia. In fact, MRTFs
are more nuclearly localized in Acta2-/- SMCs than in wild-type cells. Rather, the
hyperplasia is driven primarily by increased expression of platelet-derived growth factor
receptor β (Pdgfrb) downstream of overly active focal adhesions (unpublished data).
Follow-up work on a transgenic mouse model harboring a missense mutation in Acta2
suggests that similar pathways may drive hyperplasia in patient SMCs in conjunction
with the SRF:MRTF axis, which is activated by the pools of unpolymerized actin.
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Sporadic TAAD
A majority of patients with TAAD do not have any family history of the disease.
Well-established risk factors for aneurysm formation in non-familial patients include
hypertension, bodybuilding, smoking, and stimulant drug use (e.g. cocaine).
Hypertension is the most important risk factor for TAAD, suggesting that increased
pressures on the aortic wall may underlie aneurysm pathogenesis [43,45]. Patients at risk
for TAAD are thus advised to closely monitor their blood pressures, and doctors are
prescribing blood pressure management medications such as beta-blockers to keep
pressures low and decrease the acceleration of aortic blood flow [43].
Although sporadic TAAD patients are unlikely to have a causative genetic
mutation underlying their disease, genetic factors may contribute to disease risk in these
patients. Several recent studies have looked at potential genetic factors in non-familial
TAAD, and these studies have confirmed that the pathways and mechanisms identified
in familial patients are more widely applicable in understanding the disease. For
example, single nucleotide polymorphisms (SNPs) in FBN1, the gene responsible for
MFS, were highly associated with TAAD in a genome-wide association study (GWAS)
[69]. A copy number variant (CNV) screen in sporadic TAAD patients identified a
number of genomic deletions and duplication in these patients. Pathway analysis of the
genes involved in these CNVs revealed a high proportion of these alterations hit genes
involved in SMC contraction and focal adhesions [70]. These broad screens searching
for genetic factors contributing to non-familial TAAD thus hit genes and pathways
already known to be critically involved in inherited forms of the disease.
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Single nucleotide polymorphisms (SNPs) are single amino acid changes in the
genetic code that are common in the general population, and can be associated with a
very low increase in risk of common diseases, usually a magnitude of 1-2%. While it is
useful to look broadly at the genes where SNPs lie, the utility of identifying SNPs as
either a diagnostic or a therapeutic tool is low. Mendelian mutations, by contrast, are
extremely rare in the population, and correlate almost 100% with disease development.
Thus, although studying these mutations allows specific identification of a few at-risk
individuals, and certainly, as described above, contributes to overall understanding of the
mechanisms of disease, they do not on their own allow us to study unique geneenvironment interactions or to predict pathways that influence disease in a much broader
spectrum of patients. A third class of genetic contributors to disease, known as rare
variants, has both an intermediate allele frequency and an intermediate contribution of
increased disease risk. The goal of this dissertation is to study the role of two specific
rare variants in the MYH11 gene in the pathogenesis of TAAD.

Rare variants, MYH11, and TAAD
Although Mendelian mutations in the MYH11 gene have been associated with
TAAD, the mutations identified in those families were uniformly large deletions or
frameshift mutations. The exception is a single missense mutation identified in the
converter domain: R712Q, which is predicted to dramatically alter the movement of the
myosin head [68]. However, sequencing data shows that nonsynonymous missense
alterations in MYH11 are not uncommon in the general population. Furthermore, these
alterations were more prevalent in patients with vascular disease than in vascular
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disease-free controls. Therefore, we asked whether these single amino acid alterations
might be contributing an increased risk of vascular disease in the general population. We
chose to study a particular missense alteration, a substitution of a cysteine for an arginine
at position 247.
At the same time, results from our initial CNV screen also yielded a surprising
finding: a 12-fold enrichment in duplications at the 16p13 locus in the TAAD population
compared with the control population. Directly in the middle of the duplicated region
lies the MYH11 gene. Based on our previous results implicating MYH11 in TAAD, we
hypothesized that MYH11 duplications were the causative risk factor within the 16p13
duplication region. Therefore, we hypothesized that either a missense mutation in
the MYH11 gene (R247C) or the duplication of the gene would alter SMC
phenotype and increase the risk of TAAD.
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Chapter 2: Rare Nonsynonymous Variant in Smooth Muscle Myosin, Myh11
R247C, Alters SMC Phenotype
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Introduction
For initial analysis of rare variants in MYH11, we selected the most recurrent rare
missense mutation from our vascular disease cohort, R247C. Sequencing results indicate
that this variant is found in patients with TAAD, intracranial aneurysms, early onset
strokes, and other vascular diseases (unpublished data). This variant alters an arginine
residue within the actin binding domain of the myosin motor head to a cysteine.
Additionally, a mutation in the paralogous gene MYH7, encoding the cardiac β-myosin
heavy chain, was previously identified to cause inherited cardiomyopathy [71,72]. Thus,
the R247C variant is a good candidate for investigating the role of rare variants in
MYH11 in vascular disease pathogenesis.

Table 2.1 Enzymatic activity of WT and R247C myosin. Reprinted with permission
from Wolters Kluwer Health. [Rare, Nonsynonymous Variant in the Smooth MuscleSpecific Isoform of Myosin Heavy Chain, MYH11, R247C, Alters Force Generation in the
Aorta and Phenotype of Smooth Muscle CellsNovelty and Significance. Kuang SQ,
Kwartler CS, Byanova KL, Pham J, Gong L, Prakash SK, Huang J, Kamm KE, Stull JT,
Sweeney HL, Milewicz DM. Circulation Research 2012.]
Dr. H. Lee Sweeney’s lab at the University of Pennsylvania performed an initial
in vitro characterization of the variant by expressing a heavy meromyosin (HMM)
construct of MYH11 with and without the introduced R247C mutation in a baculovirus
system. The resulting proteins were purified and put through a number of in vitro assays
to characterize their function. First, actin-activated ATPase assays were performed using
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phalloidin-stabilized actin molecules. Next, transient kinetic assays were performed to
assess the rates of ADP release and inorganic phosphate release following the ATPase
reaction. Finally, an in vitro motility assay was performed to assess the sliding filament
velocity of actin moving along the myosin filaments. In each assay, the R247C mutant
myosin molecules were significantly slower than the wild-type myosin molecules at
performing these actions (Table 2.1). These results suggest that the R247C mutation
decreases the enzymatic activity of the myosin motor and impedes its force generation,
and further suggest that this alteration may contribute to disease pathogenesis.

Figure 2.1 Generation of Myh11R247C/R247C knockin mice. Schematic showing the
design of the targeting strategy for generation of Myh11R247C/R247C knockin mice.
Reprinted with permission from Wolters Kluwer Health. [Rare, Nonsynonymous Variant
in the Smooth Muscle-Specific Isoform of Myosin Heavy Chain, MYH11, R247C,
Alters Force Generation in the Aorta and Phenotype of Smooth Muscle CellsNovelty and
Significance. Kuang SQ, Kwartler CS, Byanova KL, Pham J, Gong L, Prakash SK,
Huang J, Kamm KE, Stull JT, Sweeney HL, Milewicz DM. Circulation Research 2012.]
Next, we generated a knock-in mouse model carrying the R247C mutation
(Figure 2.1). The targeting vector contained a positive neo selection cassette and a
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negative tk selection cassette; the selection cassettes were enclosed within two inserted
Frt sites for later removal. The mutation was introduced flanked by two loxP sites to
allow future generation of a knock-out model. The mutation lies in exon 7 of the coding
region, and the targeting vector spanned from intron 6 to intron 9. After construction, the
vector was linearized and introduced via electroporation into 129SvEv mouse embryonic
stem cells. Positive and negative selection were performed to screen for successfully
transfected cells, and Southern blot analysis confirmed appropriate targeting. Finally, the
targeted stem cells were injected into C57Bl6 blastocysts to generate founder mice,
which were then bred with 129SvEv mice carrying the FLPeR recombinase which
removed the Frt-flanked selection cassettes. The final knockin mice were thus generated
as mixed 129SvEv and C57Bl6 background.
The Stull lab at University of Texas Southwestern Medical Center perfomed
aortic contractility assays on the newly generated knockin mice. Briefly, aortic rings
from the thoracic ascending, thoracic descending, and abdominal aorta were mounted on
an isometric force apparatus. After equilibration, the rings were subjected to contractile
stimuli, KCl or phenylephrine, and force generation was measured. Aortic rings from the
Myh11R247C/R247C mice had significantly reduced force generation when compared with
wild-type in all three tested tissue locations (Figure 2.2a). Tissue was snap-frozen after
the initial analysis, and lysates were subjected to urea/glycerol gel electrophoresis to
separate phosphorylated myosin light chain from non-phosphorylated. There was no
difference in regulatory light chain phosphorylation from the Myh11R247C/R247C mice
compared with wild-type, indicating that reduced force generation was due to intrinsic
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properties of the myosin motor rather than a defect in the signaling leading to
contraction (Figure 2.2b).

Figure 2.2 Decreased contractility without aortic disease in Myh11R247C/R247C mice. A)
Decreased force generation by Myh11R247C/R247C knockin mice. B) No change in the myosin
light chain phosphorylation in Myh11R247C/R247C knockin mice. C) Myh11 genotype has no
effect on aortic diameter. D) Myh11R247C/R247C knockin mice have no pathologic signs of
aortic disease. Reprinted with permission from Wolters Kluwer Health. [Rare,
Nonsynonymous Variant in the Smooth Muscle-Specific Isoform of Myosin Heavy Chain,
MYH11, R247C, Alters Force Generation in the Aorta and Phenotype of Smooth Muscle
CellsNovelty and Significance. Kuang SQ, Kwartler CS, Byanova KL, Pham J, Gong L,
Prakash SK, Huang J, Kamm KE, Stull JT, Sweeney HL, Milewicz DM. Circulation
Research 2012.]
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Despite the decrease in aortic contractility, Myh11R247C/R247C mice had no signs of
spontaneous vascular disease. The blood pressure of the mice was unaffected, and
histopathologic examination of the aorta showed no dilatation and no medial
degeneration (Figure 2.2c,d). Elastin fibers remained intact, and there was no
accumulation of proteoglycans. Additionally, the mice had no decrease in survival or
reproductive function compared with wild-type. These results show that decreased
contractility alone does not lead to aortic disease.

Figure 2.3 Increased vascular injury response in Myh11R247C/R247C mice. A/B/C)
Increased neointimal proliferation after carotid ligation in Myh11R247C/R247C knockin
mice. A shows histology from 21 days post injury. B and C show quantitation of this
effect over three weeks post surgery. Reprinted with permission from Wolters Kluwer
Health. [Rare, Nonsynonymous Variant in the Smooth Muscle-Specific Isoform of
Myosin Heavy Chain, MYH11, R247C, Alters Force Generation in the Aorta and
Phenotype of Smooth Muscle CellsNovelty and Significance. Kuang SQ, Kwartler CS,
Byanova KL, Pham J, Gong L, Prakash SK, Huang J, Kamm KE, Stull JT, Sweeney HL,
Milewicz DM. Circulation Research 2012.]
Because the R247C alteration is a rare variant, not a Mendelian mutation, these
results are not surprising. We hypothesized that a second hit may be needed to induce a
disease phenotype in these mice. Because this variant is found in patients with occlusive
as well as aneurysmal disease, we initially used an injury model of carotid artery
ligation. Briefly, the left common carotid artery is tied off just proximal to the

31

bifurcation, and the mice are allowed to recover. This is a well-established model of
vascular injury, and the vessels undergo extensive remodeling below the injury. The end
result of this remodeling is a thickening of the vessel wall as SMCs proliferate and
migrate through the internal elastic lamina. The new layer of SMCs is called the
“neointima.” The thickness of the neointima left after injury correlates with the
proliferative and migratory response of the SMCs to injury, and the Myh11R247C/R247C
mice had significantly thicker neointimal layers (Figure 2.3a,b). These results
suggested that the Myh11 R247C rare variant might predispose to occlusive diseases by
increasing the proliferative response of SMCs.
For the first aim of this project, we thus proceeded to further examine the
phenotype of SMCs from Myh11 R247C knockin mice to determine a mechanistic link
between the R247C alteration and a possible increase in cellular proliferation.

Materials and Methods
“Vascular SMCs Isolation and Culture
To isolate primary mouse aortic SMCs, aortas were isolated (from the aortic root
to the renal arterial bifurcation) from 6-week old WT and Myh11R247C/R247C
knock-in mice. Whole aortas were collected under sterile conditions and put into
biopsy medium (Table 2.3). Ascending aorta/arch and descending aortas were
separated after the origin of the left subclavian artery. The adventitia was
removed, and the remaining medial layer of aorta was chopped into small pieces
and put to digestion overnight for 16 h in 5 ml of aortic biopsy medium
supplemented with 0.1 mg/ml of collagenase type I, 0.019 mg/ml of elastase type
I and 0.0250 mg/ml of soybean trypsin inhibitor. At the end of incubation, the
digestion was stopped with 2.5 ml of fetal bovine serum and 2.5 ml of complete
SMC medium (Table 2.3). Cells and tissue were spun down, resuspended in
complete SMC medium and seeded into flasks for further experiments. The
identity of these cells as SMCs was verified by staining for smooth muscle αactin (mouse monoclonal antibody; Sigma-Aldrich, St. Louis, MO) at each
passage (95% of cells stained positive for smooth muscle α-actin). SMCs were
cultured in complete SMC medium in a 37°C, 5% CO2-humidified incubator.
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Three independent cell lines each were explanted from WT mice, Myh11R247C/+,
and Myh11R247C/R247C mice, using aortas pooled from three to five mice per
genotype per explant. The results presented are representative of at least two
independent experiments done on each line of SMCs using passage-matched WT
and Myh11R247C/R247C SMCs. All studies were performed on SMCs at less than
passage 5.
Immunoblot Analyses
Aortic tissues or cultured cells were homogenized and lysed in RIPA buffer
(Table 2.3) supplemented with protease inhibitor cocktail (Sigma-Aldrich, St.
Louis, MO) and phosphatase inhibitor cocktail (Sigma-Aldrich, St. Louis, MO).
Protein (5μg) for each sample was separated on Tris–HCl gel (Bio-Rad, Hercules,
CA) by SDS-PAGE, followed by transfer to polyvinylidene difluoride
membranes (Millipore, Bedford, MA). Membranes were immunoblotted with
primary antibody and the appropriate horseradish peroxidase-conjugated
secondary antibody (Jackson ImmunoResearch Laboratories, West Grove, PA).
Immunoblots blots were visualized by the enhanced chemiluminescence
technique (GE Healthcare, Piscataway, NJ). For primary antibodies and dilutions,
see Table 2.2.
Immunofluorescence in Explanted Aortic SMCs
After cells reached confluence, they were seeded onto coverslips in six-well
plates with the density of 13 cells/mm2 for 24 h. For MRTF-A staining, Cells
were starved in 1% serum media for 24 hours, plus/minus inhibitorsand fixed
with 4% paraformaldehyde for 10 min. Permeabilization was performed in PBS
containing 0.1% Triton X-100 and blocking of nonspecific binding sites was
performed in PBS containing and 5% donkey serum. Coverslips were then
treated with primary antibody (anti-MRTFA (Santa Cruz Biotechnology, Santa
Cruz, CA), 1:100) overnight followed by fluorescein isothiocyanate-conjugated
secondary antibody (1:100, Jackson ImmunoResearch Laboratories, West Grove,
PA) for 1 h. Nuclei were counterstained with DAPI (Vector Laboratories,
Burlingame, CA), and then randomly chosen fields on each coverslip were
imaged by confocal microscopy (Nikon A1R, Nikon Instruments, Melville, NY).
For focal adhesion staining, cells were starved in 1% serum media for 24 hours
then treated with or without 10ng/mL TGF-β1 for 48 hours. The same fixation
and staining protocol described above was used with primary antibodies antivinculin (Sigma-Aldrich, St. Louis, MO) and anti-phospho-FAK (Y397)
(Millipore, Bedford, MA). For α-actin staining, cells were starved in 1% serum
media for 12 hours, followed by 10ng/mL TGF-β1 for 72 hours. CN03 treatment
was added for 24 hours after completion of TGF-β1 incubation. Again, the same
fixation and staining protocol were used with primary antibody anti α –SMA
(Sigma-Aldrich, St. Louis, MO). For phalloidin staining, coverslips were
incubated with Texas Red-labeled phalloidin (1:40 in blocking solution)
(Molecular Probes, Eugene, OR) for 30 min.
Analysis of Immunofluorescence Images
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All analyses were performed using the Nikon NIS Elements software. Pearson
coefficients for colocalization of blue (DAPI stained nuclei) and green (MRTFA)
pixels were calculated for at least 15 cells per slide on at least 3 slides for each
bar shown on the graph. The same protocol was used to obtain Pearson
coefficients for colocalization of green (α-actin) and red (phalloidin) pixels for
Figure 6. Individual focal adhesion size was calculated for at least 30 adhesions
per cell on at least 10 cells per genotype using the Nikon NIS Elements
measurement tool.

Table 2.2 Antibodies used in Chapter 2.
Cell Proliferation Assays
Proliferation of SMCs was quantified using by the incorporation of BrdU. Briefly,
SMCs were seeded in 96-well plates (20,000 cells/ well) and grown for 24 hours
in SmBm (see SMCs Isolation and Culture section for details) containing 20%
FBS. The cells were serum-starved in SmBm containing 1% FBS and plus/minus
inhibitors for 30 minutes prior to the addition of BrdU reagent. After 24 hours of
incubation, BrdU incorporation was quantified by ELISA according to the
manufacturer’s instructions (Millipore, Bedford, MA). Inhibitors include
NSC23766 (Rac inhibitor) (Tocris Bioscience, Ellisville, MO), PF537228 (FAK
inhibitor) (Tocris Bioscience, Ellisville, MO), and CN03 (Rho Activator)
(Cytoskeleton, Denver, CO).
Rho and Rac Activation Assays
RhoA and Rac1 activation were quantified using G-LISA assays (Cystoskeleton,
34

Denver, CO) performed according to the manufacturer’s specifications. Briefly,
cells were seeded on 6cm dishes (200,000 cells/dish) and grown for 24 h in
SmBm containing 20% FBS. The cells were serum-starved in SmBm containing
1% FBS for 24 hours, then treated +/- lypophosphatidic acid (Sigma-Aldrich, St.
Louis, MO) for 15 minutes. Cells were lysed in the provided lysis buffer and
lysates were snap frozen. Protein, (0.5 μg) was loaded per well of the provided
ELISA plate, and activated Rac1 and RhoA were quantified by ELISA assay.
F/G actin Assay
Polymerization of actin was assayed using an F/G actin assay (Cytoskeleton,
Denver, CO) performed according to the manufacturer’s specifications. Briefly,
cells were seeded on 10cm dishes (900,000 cells/dish) and grown for 24 h in
SmBm containing 20% FBS. The cells were serum-starved in SmBm containing
1% FBS for 24 hours, then lysed and homogenized in the provided lysis buffer.
Samples were pelleted in an ultracentrifuge (Optima TLX Ultracentrifuge, Rotor
TLA-110, Beckman Coulter, Brea, CA) at 55,000 rpm for 1 hour at 37°C. Pellets
and supernatant fractions were separately processed and processed by SDSPAGE for subsequent immunoblot analysis.

Table 2.3 Buffer compositions used in Chapter 2.
RNA Extraction and QuaQuantitative Real-time PCR
Total mouse aortic tissue or primary vascular SMC cellular RNA was extracted
with Trizol (Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol.
Reverse transcription reactions were performed using the High Capacity cDNA
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Archive Kit (Life Technologies, Carlsbad, CA) according to the manufacturer’s
protocol. For quantitative real-time PCR analysis of mRNA expression, TaqMan
probes were purchased from Applied Biosystems and analyzed using an Applied
Biosystems Prism 7900 HT Sequence Detection System (Applied Biosystems,
Foster City, CA) according to the manufacturer’s protocol. Experiments were
performed in triplicate. Gapdh was used as the endogenous control.
Statistical Analysis
All values are expressed as means ± standard deviation. Statistical differences
between WT and mutant mice or cells were analyzed by a Student’s t-test.
Morphometric analysis of carotid artery was done by one-way ANOVA.
Differences were considered statistically significant at values of P <0.05. Data
for cell culture experiments represent three experiments in triplicates using
separate cultures.” [73]
Quoted text reprinted with minimal modification with permission from Wolters
Kluwer Health [Rare, Nonsynonmyous Variant in the Smooth Muscle Specific
Isoform of Myosin Heavy Chain, MYH11, R247C, Alters Force Generation in the
Aorta and Phenotype of Smooth Muscle Cells. Kuang SQ, Kwartler CS, Byanova
KL, Pham J, Gong L, Prakash SK, Huang J, Kamm KE, Stull JT, Sweeney HL,
Milewicz DM. Circ Res. 2012.]

Figure 2.4 Myh11R247C/R247C SMCs are dedifferentiated. A) Increased cellular
proliferation in Myh11R247C/R247C SMCs. B,C) Decreased expression of contractile genes
(B) and proteins (C) in Myh11R247C/R247C SMCs. Reprinted with permission from Wolters
Kluwer Health. [Rare, Nonsynonymous Variant in the Smooth Muscle-Specific Isoform
of Myosin Heavy Chain, MYH11, R247C, Alters Force Generation in the Aorta and
Phenotype of Smooth Muscle CellsNovelty and Significance. Kuang SQ, Kwartler CS,
Byanova KL, Pham J, Gong L, Prakash SK, Huang J, Kamm KE, Stull JT, Sweeney HL,
Milewicz DM. Circulation Research 2012.]
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Results
Myh11R247C/R247C smooth muscle cells are dedifferentiated
Consistent with the results of the in vivo injury model study, Myh11R247C/R247C
SMCs proliferated significantly more rapidly in culture compared with wild-type cells
(Figure 2.4a). Because proliferation and expression of contractile markers are often
negatively correlated, we next looked at both gene expression and protein accumulation
of commonly used contractile markers: Acta2 (SM-actin), Cnn1 (calponin), and Myh11
(SM-MHC). All three genes were expressed at significantly lower levels in
Myh11R247C/R247C SMCs than in wild-type cells, and Western blot analysis showed
concomitantly reduced protein levels (Figure 2.4b,c). Treatment with TGF-β1, which
drives increased contractile gene expression in wild-type SMCs, was unable to rescue
the decreased expression seen in Myh11R247C/R247C SMCs (data not shown). These initial
results suggest that the Myh11R247C/R247C SMCs are canonically dedifferentiated.
We next assessed whether the SRF:MRTF axis were responsible for the observed
dedifferentiated phenotype. Immunofluorescence revealed a significant shift in the
localization of MRTF-A from predominantly nuclear in wild-type cells to predominantly
cytoplasmic in Myh11R247C/R247C SMCs (Figure 2.5c). MRTF localization is dependent
on actin filament formation, so we asked whether there was an increased unpolymerized
actin fraction in the knockin cells. Immuofluorescent analysis shows thick filaments of
smooth muscle α-actin spanning the cell body in wild-type SMCs, but a combination of
thinner, shorter filaments and unpolymerized α-actin in Myh11R247C/R247C SMCs (Figure
2.5a). These results were confirmed using an ultracentrifugation based assay that
separates polymerized from unpolymerized actin: a comparison of α-actin content in the
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supernatant compared with the pellet shows a significantly altered ratio of polymerized
to unpolymerized actin in the Myh11R247C/R247C SMCs (Figure 2.5b). Thus,
unpolymerized actin pulls MRTF out of the nucleus, leading to decreased contractile
gene expression and increased cellular proliferation in Myh11R247C/R247C SMCs. However,
the link between a mutation in Myh11 and decreased actin filament formation remained
to be determined.

Figure 2.5 The SRF;MRTF axis drives dedifferentiation in Myh11R247C/R247C SMCs. A)
Immunofluorescences shows decreased numbers of SM-actin filaments (green) in
Myh11R247C/R247C SMCs. B) Ultracentrifugation assay shows decreased F-actin fraction in
Myh11R247C/R247C SMCs . C) Decreased nuclear localization of MRTF in Myh11R247C/R247C
SMCs. Reprinted with permission from Wolters Kluwer Health. [Rare, Nonsynonymous
Variant in the Smooth Muscle-Specific Isoform of Myosin Heavy Chain, MYH11, R247C,
Alters Force Generation in the Aorta and Phenotype of Smooth Muscle CellsNovelty and
Significance. Kuang SQ, Kwartler CS, Byanova KL, Pham J, Gong L, Prakash SK,
Huang J, Kamm KE, Stull JT, Sweeney HL, Milewicz DM. Circulation Research 2012.]

Altered focal adhesions in Myh11R247C/R247C SMCs
As described in Chapter 1, focal adhesions are the force sensors of the cell,
located at the plasma membrane. Intracellular force generation, via myosin contractility,
drives maturation of focal adhesions. Impairment of myosin contractility using
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blebbistatin prevented focal adhesion maturation in fibroblasts, resulting in smaller
adhesions and a change in the composition of the complexes from enrichment of RhoA
activators in mature adhesions to enrichment of Rac1 activators in less mature adhesions
[74]. Because the R247C rare variant causes a decrease in myosin force generation, we
asked whether the focal adhesions in Myh11R247C/R247C SMCs might similarly be less
mature. Vinculin is a commonly used marker for focal adhesions, as its protein content
within the adhesion does not change with maturation [75]. Immunofluorescence for
vinculin showed significantly smaller focal adhesions in Myh11R247C/R247C SMCs.
Consistent with the gene expression results, focal adhesions in Myh11R247C/R247C SMCs
did not increase in size after TGF-β1 treatment while focal adhesions in wild-type SMCs
became larger, increasing the difference in size between the two cell types (Figure 2.6a).
Secondly, we assessed cellular levels of Rac1 and RhoA activation as a proxy for
the change in composition of the focal adhesions. Rac1 activation was significantly
increased in Myh11R247C/R247C SMCs compared with wild-type cells at baseline (Figure
2.6b). RhoA activation was slightly decreased at baseline, but the effect became
significant after a 5-minute stimulation with the known RhoA activator lysophosphatidic
acid (LPA) (Figure 2.6c). These results are consistent with less mature focal adhesions
in Myh11R247C/R247C SMCs.

39

Figure 2.6 Altered focal adhesions in Myh11R247C/R247C SMCs. A)
Immunofluorescences for vinculin (green) shows smaller focal adhesions in
Myh11R247C/R247C SMCs with and without TGF-β stimulation. B,C) Increased Rac1 (B)
and decreased RhoA (C) activation in Myh11R247C/R247C SMCs . Reprinted with
permission from Wolters Kluwer Health. [Rare, Nonsynonymous Variant in the
Smooth Muscle-Specific Isoform of Myosin Heavy Chain, MYH11, R247C, Alters
Force Generation in the Aorta and Phenotype of Smooth Muscle CellsNovelty and
Significance. Kuang SQ, Kwartler CS, Byanova KL, Pham J, Gong L, Prakash SK,
Huang J, Kamm KE, Stull JT, Sweeney HL, Milewicz DM. Circulation Research
2012.]
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Figure 2.7 CN03 treatment drives actin polymerization in Myh11R247C/R247C SMCs. A)
Treatment with CN03 increases activation of RhoA . B) Treatment with CN03 for 4 or 24
hours increases nuclear localization of MRTFA in Myh11R247C/R247C SMCs (C) Treatment
with CN03 for 24 hours drives actin polymerization in Myh11R247C/R247C SMCs . Reprinted
with permission from Wolters Kluwer Health. [Rare, Nonsynonymous Variant in the
Smooth Muscle-Specific Isoform of Myosin Heavy Chain, MYH11, R247C, Alters Force
Generation in the Aorta and Phenotype of Smooth Muscle CellsNovelty and Significance.
Kuang SQ, Kwartler CS, Byanova KL, Pham J, Gong L, Prakash SK, Huang J, Kamm
KE, Stull JT, Sweeney HL, Milewicz DM. Circulation Research 2012.]

41

Pharmacologic activation of RhoA rescues the dedifferentiated phenotype of
Myh11R247C/R247C SMCs
RhoA activation in SMCs drives polymerization of actin [42]; thus, we asked
whether activating RhoA in Myh11R247C/R247C SMCs could rescue the dedifferentiated
phenotype. We used a pharmacological compound called “CN03” derived from a
bacterial endotoxin. CN03 works by deaminating glutamine residue 63, causing RhoA to
become constitutively active (Figure 2.7a). Treatment of Myh11R247C/R247C SMCs with
CN03 successfully increased actin polymerization (Figure 2.7c). Additionally, MRTF-A
localization became more nuclear following CN03 treatment, and expression of
contractile genes and proteins were significantly increased Figure 2.7b, Figure 2.8a,b).
Thus, the lack of maturation of the focal adhesions, and the resulting decrease in RhoA
activation, drives the dedifferentiated phenotype in Myh11R247C/R247C SMCs.
However, treatment with CN03 only partially prevented the increased cellular
proliferation of Myh11R247C/R247C SMCs (Figure 2.8c). This result implies that the
SRF:MRTF axis alone is incompletely responsible for driving proliferation in
dedifferentiated SMCs, and suggests that alternatively dedifferentiation merely sensitizes
SMCs to proliferative stimuli. The next question was which proliferative stimuli were
driving the increased cellular proliferation of Myh11R247C/R247C SMCs.
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Figure 2.8 CN03 treatment drives SMC differentiation in Myh11R247C/R247C SMCs.
A, B) Treatment with CN03 increases expression of contractile gene mRNA (A) after
4 hours and proteins (B) after 24 hours in Myh11R247C/R247C SMCs. C) Treatment with
CN03 for 24 hours partially blocks proliferation in Myh11R247C/R247C SMCs. D)
Densitometry quantification of B. Reprinted with permission from Wolters Kluwer
Health. [Rare, Nonsynonymous Variant in the Smooth Muscle-Specific Isoform of
Myosin Heavy Chain, MYH11, R247C, Alters Force Generation in the Aorta and
Phenotype of Smooth Muscle CellsNovelty and Significance. Kuang SQ, Kwartler
CS, Byanova KL, Pham J, Gong L, Prakash SK, Huang J, Kamm KE, Stull JT,
Sweeney HL, Milewicz DM. Circulation Research 2012.]
Focal adhesion kinase drives proliferation in Myh11R247C/R247C SMCs
Focal adhesion kinase is a signaling protein localized to focal adhesions, which
drives activation of multiple downstream pathways including a number of proliferative
pathways like MAPK [76]. Focal adhesion kinase is also known to be more active in less
mature focal adhesions. Therefore, we assessed whether focal adhesion kinase was more
active in Myh11R247C/R247C SMCs, and whether this increased activation led to the
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observed proliferative phenotype. Both immunofluorescence and Western blot analyses
indicate an increase in activated focal adhesion kinase in Myh11R247C/R247C SMCs, as
assessed by phosphorylation of tyrosine 397 (Figure 2.9a,b). Similarly, downstream
activation of Akt was concomitantly increased in Myh11R247C/R247C SMCs as well.
Treatment of Myh11R247C/R247C SMCs with an inhibitor of focal adhesion kinase,
PF-573228, did not have any effect on actin polymerization, MRTF-A localization, or
contractile gene expression (data not shown). However, PF-228 did partially and
significantly blunt cellular proliferation in Myh11R247C/R247C SMCs (Figure 2.9c). This
result suggests that focal adhesion kinase is one proliferative stimulus that contributes to

Figure 2.9 Focal adhesion kinase activation Myh11R247C/R247C SMCs. A, B)
Activation of FAK in Myh11R247C/R247C SMCs shown by immunofluorescence (A) and
Western blot (B). C) Treatment with an inhibitor of FAK, PF537228 for 24 hours
partially blocks proliferation in Myh11R247C/R247C SMCs. Reprinted with permission
from Wolters Kluwer Health. [Rare, Nonsynonymous Variant in the Smooth MuscleSpecific Isoform of Myosin Heavy Chain, MYH11, R247C, Alters Force Generation in
the Aorta and Phenotype of Smooth Muscle CellsNovelty and Significance. Kuang
SQ, Kwartler CS, Byanova KL, Pham J, Gong L, Prakash SK, Huang J, Kamm KE,
Stull JT, Sweeney HL, Milewicz DM. Circulation Research 2012.]
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the phenotype seen in Myh11R247C/R247C SMCs.

SMCs in Myh11R247C/R247C aortas are not dedifferentiated
Although the phenotype and mechanism have been established in SMCs in
culture, the question remains whether there is any alteration in SMC phenotype in vivo in
Myh11R247C/R247C tissues. Ascending aortic tissue from Myh11R247C/R247C and wild-type
mice was harvested, but there was no difference in expression levels of contractile genes
or proteins in vivo (Figure 2.10a,b). Similarly, staining for phospho-histone 3 (PH3), a
marker of proliferating cells [77], shows no increase in proliferating SMC nuclei in the
Myh11R247C/R247C aortas (Figure 2.10c,d). Finally, analysis of Rac1 and RhoA activation
reveals no difference between Myh11R247C/R247C and wild-type aortas (Figure 2.10e,f).
Thus, this phenotype occurs in Myh11R247C/R247C SMCs after explanting, but is not
prevalent within the aortic tissue. These results suggest that this phenotype may be
injury-induced, as explanting SMCs induces an injury-like response and carotid injury
induced a proliferative phenotype in Myh11R247C/R247C mice.
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Figure 2.10 Myh11R247C/R247C SMCs within the aortic wall are not dedifferentiated. A,
B) Levels of contractile genes (A) and proteins (B) are similar betweenMyh11R247C/R247C
and wild-type aortas. C, D) No change in phospho-histone 3 staining in Myh11R247C/R247C
aortas, (D) shows quantitation of positive cells. E, F) No change in Rac1 (E) or RhoA (F)
activation in Myh11R247C/R247C aortas. Reprinted with permission from Wolters Kluwer
Health. [Rare, Nonsynonymous Variant in the Smooth Muscle-Specific Isoform of
Myosin Heavy Chain, MYH11, R247C, Alters Force Generation in the Aorta and
Phenotype of Smooth Muscle CellsNovelty and Significance. Kuang SQ, Kwartler CS,
Byanova KL, Pham J, Gong L, Prakash SK, Huang J, Kamm KE, Stull JT, Sweeney HL,
Milewicz DM. Circulation Research 2012.]
Discussion
The R247C alteration introduced into the mouse Myh11 gene causes a decrease
in aortic contractility but does not lead to aortic disease. However, carotid injury did lead
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to an increased vascular proliferative response, suggesting that a second hit can induce
disease in Myh11R247C/R247C mice. SMCs explanted from Myh11R247C/R247C mice are dedifferentiated, with reduced expression of contractile genes and increased proliferation.
The canonical SRF: MRTF axis drives the observed dedifferentiation in Myh11R247C/R247C
SMCs: pools of unpolymerized actin sequester the transcriptional coactivator MRTFs in
the cytoplasm, preventing the transcription of SMC contractile genes.
In conjunction with the dedifferentiated phenotype of Myh11R247C/R247C SMCs,
focal adhesions in these cells are less mature. Focal adhesions (FAs) are dynamic protein
complexes at the cell membrane that promote adhesion of the cells to the extracellular
matrix and also drive signaling in response to changes in force generation [78].
Increasing intracellular tension, driving by acto-myosin contractility, promotes focal
adhesion maturation. As FAs mature, they both increase in size and change in
composition: nascent FAs form, then as actin stress fibers begin to polymerize at the site
of the complexes additional proteins, including paxillin, are recruited [79]. Further force
generation, in form of myosin motor function, is required for complete maturation of
FAs. A recent paper looked at the composition of FAs in fibroblasts with or without
treatment with the myosin motor poison blebbistatin. In the absence of myosin motor
function, FAs contained Rac1 activating molecules like β-pix, while mature FAs in cells
with uncompromised myosin motors were alternatively enriched for RhoA activators
like testin [74]. RhoA has previously been shown to regulate actin polymerization, and
downstream of polymerization also regulates SMC differentiation [42]. Modulation of
RhoA signaling dramatically impacts contractile gene expression: knockdown of RhoA
reduces SMC differentiation, while constitutive activation of RhoA increases expression

47

of marker genes [80]. Thus, FA maturation drives a positive feedback loop by increasing
activation of RhoA, driving further differentiation of SMCs, maintains the intracellular
force, and leading to further FA maturation.
The R247C variant in Myh11 causes decreased capacity for force generation by
the mutant smooth muscle myosin motor. FAs in Myh11R247C/R247C SMCs are therefore
unable to fully mature due to decreased intracellular force generation. In fact,
pharmacologic activation of RhoA completely rescued the dedifferentiated phenotype of
Myh11R247C/R247C SMCs, suggesting that the loss of FA maturation, and concomitant
decrease in RhoA activation, is the causative factor driving dedifferentiation.
Importantly, SMCs also express two non-muscle myosin heavy chain molecules (Myh9
and Myh10), but these fully functional, less specialized myosin molecules were unable to
compensate for the mutant smooth muscle myosin to drive normal FA maturation. Thus,
this part of my dissertation proves that smooth muscle-specific myosin function is
necessary to drive FA maturation in SMCs, and that loss of that motor function can
disrupt SMC differentiation by preventing FA maturation.
However, in the intact, uninjured aorta, Myh11R247C/R247C SMCs show no
difference in contractile protein expression, proliferation, or RhoA activation. FAs in the
tissue are called dense plaques, which promote interactions of the complex extracellular
matrix with the contractile fibers of the SMCs through integrin receptors. The dense
plaques are constantly exposed to biomechanical stress and strain due to pulsatile blood
flow, in contrast to FAs in static culture. Loss of integrin linked kinase (ILK), a kinase
localized to focal adhesions that binds to both integrins and components of the actin
cytoskeleton, led to a similar cellular phenotype in vitro as the R247C mutation: loss of

48

RhoA activity and dedifferentiation of SMCs [81]. However, unlike our model, the ILK
knockout mice had a similar phenotype in vivo. Interestingly, the ILK knockout mice
have a similar phenotype to patients with MYH11 mutations: TAAD with patent ductus
arteriosus [61]. Therefore, ILK may be a potential source of RhoA activation in vivo in
the Myh11R247C/R247C aortas, or alternatively the continuous external biomechanical forces
on the aorta may compensate for the partial loss of intracellular myosin force generation
to allow maturation of the dense plaques within Myh11R247C/R247C aortic SMCs. Patients
with MYH11 mutations have more severe defects in myosin function as the mutations
identified are predicted to disrupt myosin filament formation. It may be that complete
loss of myosin force generation, like the aberrant signaling responses to external force
cues in ILK knockout mice, is sufficient to provoke a phenotype in vivo.
Surprisingly, Myh11R247C/R247C mice do not have a phenotype in other smooth
muscle tissues like the bladder, uterus, or intestines. Mice with complete Myh11
knockout die shortly after birth due to bladder and intestinal dysfunction [82], however
the Myh11R247C/R247C mice show no defects in weight gain and no alterations in
reproductive capacity. However, physiologically, SMCs in all tissues have a large
contractile reserve as myosin light chain kinase is rarely fully activated [83,84]. This
contractile reserve may protect smooth muscle tissues from the partial defect in myosin
function seen in Myh11R247C/R247C mice.
In conclusion, the R247C rare variant does disrupt smooth muscle myosin motor
function and aortic contractility, and under circumstances of vascular injury can alter
SMC phenotype due to loss of FA maturation (see model Figure 2.11). Taken together,
these data support the hypothesis that the R247C rare variant may contribute to vascular
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disease when accompanied by additional environmental or genetic risk factors. This
hypothesis will be further examined in Chapter 3.

Figure 2.11. Proposed model of phenotypic alteration in Myh11R247C/R247C SMCs.
Diagram shows a summary of findings forming a complete pathway linking the
R247C rare variant to SMC phenotypic changes.
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Chapter 3: Myh11 R247C allele modifies the aneurysm phenotype of Acta2-/- mice
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Introduction
As discussed in Chapter 2, the Myh11R247C/R247C knockin mouse model does not
show evidence of vascular disease, but at the same time, the aortas of these mice
demonstrate decreased contraction. Therefore, we sought to determine if we could elicit
aortic disease in the Myh11R247C/R247C knockin mouse by introducing a “second genetic
hit”. To test this hypothesis, we introduced the R247C rare variant in mice with
knockout of Acta2, encoding the smooth muscle α-actin. Previous studies have
extensively characterized the Acta2-/- mouse model. The initial studies done on this
mouse indicated normal vascular development and no overt signs of disease except for
difficulty recovering the blood pressure after a hypotensive stimulus [85]. However,
further characterization of Acta2-/- mice in our lab revealed a previously unappreciated
phenotype of aortic dilatation with minimal medial degeneration. In fact, histologic
examination of Acta2-/- ascending aortas showed an increased number of elastic lamellae
within the aortic wall, indicating that there is a developmental effect of this mutation
(Figure 3.1a,b). The mechanism driving the increased elastin deposition during
development is not known, however at 4 weeks of age, SMC density and positive
staining for PH3 are also increased in the wall of Acta2-/- aortas (unpublished data).
These results suggest a potential role for cellular hyperplasia in driving the
developmental phenotype of extra elastin layers.
Dilatation of the aorta in Acta2-/- mice becomes significant at 12 weeks of age,
observable both by echocardiography and also by histology (Figure 3.1c). At 6 months
of age, these aortas show preliminary signs of medial degeneration, with focal
fragmentation of elastin filaments localized near the intimal layer of the aortic wall
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Figure 3.1. Aneurysm formation in Acta2-/- mice. A B) Pathology (A) and
quantitation (B) at 4 weeks of age shows increased numbers of elastic lamellae and
increased cell density in Acta2-/- mice. C) Increased aortic diameter, measured by
histology, in Acta2-/- mice becomes significant at 2 months of age. D) Pathology at 6
months of age shows minimal medial degeneration in Acta2-/- mice. Arrows represent
sites of elastin fragmentation (elastin) or proteoglycan accumulation (Alcian blue). E)
Increased medial area in Acta2-/- aortas becomes signfiicant at 12 months of age. F)
Cell density is significantly greater in Acta2-/- aortas at 1 month of age, but normalizes
by 2 months of age. From Jiumei Cao et. al unpublished data, reprinted with
permission.
(Figure 3.1d). Minimal proteoglycan accumulation accompanies the changes in elastin.
At earlier timepoints, medial degeneration is not evident. Additionally, the thickness of
the medial layer increases over time and becomes significant relative to wild-type by one
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year of age (Figure 3.1e). However, despite the early indication of proliferative
pathology, the SMC density in the aortic wall decreases over time, and equalizes with
the wild-type cell density by 12 weeks (unpublished data) (Figure 3.1f). This result
implies that cellular hypertrophy, rather than proliferation, underlies the medial
thickening that occurs as part of the disease process.
Studies performed in other mouse models of genetically triggered aneurysms
indicate an important role for angiotensin signaling in aneurysm formation. Specifically,
aneurysm formation in a Marfan mouse model (Fbn1C1093G/+) is reversed by treatment
with the angiotensin type 1 receptor (Agtr1) blocker, losartan [54]. Proteoglycan
accumulation and elastin fiber fragmentation were also significantly blunted by losartan
treatment. As a result of these studies, our lab initiated a treatment trial of the Acta2-/mice with losartan. Similar to the Marfan mouse model, aortic dilatation in Acta2-/- mice
is ameliorated by losartan according to our preliminary data (unpublished data). Taken
together, the data accumulated so far indicates that increased angiotensin receptor type Idriven signaling may underlie significant portions of the aneurysmal pathology.
The role of decreased contractility in driving aneurysm formation remains to be
fully elucidated. The genetic lesions identified thus far are all expected to disrupt the
elastin-contractile unit, and thus would affect the response of SMCs to biomechanical
forces. However, the Myh11R247C/R247C mouse model has decreased aortic contractility
but does not develop aortic disease, suggesting that additional signals are necessary to
induce pathologic changes. Those signals have yet to be identified, but may include
increased activation of angiotensin receptor signaling. Nonetheless, the relationship
between loss of contractility and aortic disease remains incompletely characterized.
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The goal of this study is first to determine whether the R247C rare variant in
Myh11 can act as a modifier gene for aortic disease either by increasing or accelerating
the presentation of the disease in an established model of aneurysm formation (Acta2-/mice) or by inducing disease in conjunction with a second, non-disease causing variant
(Acta2+/- mice). Secondly, we hope to use this system to evaluate the potential role of
contractile dysfunction and signaling changes in driving aneurysm formation.

Materials and Methods
Mouse breeding scheme
Acta2-/- male mice on a pure C57Bl/6 background were crossed with
Myh11R247C/R247C female mice on a mixed C57Bl/6 and 129sV background. The resulting
pups were all Acta2+/- Myh11R247C/+. These F1 pups were bred to each other to result in
all 9 possible Acta2 Myh11 genotypes. All mice used for the study were 75% C57Bl/6
and 25% 129sV background from the same generation of crosses (F2). For n numbers of
mice enrolled in each arm of the study, see Table 3.1.

Table 3.1 n numbers of mice per genotype for each aspect of the study.
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Echocardiography scanning and analysis
We used 6-8 mice per genotype. Aortic diameter was assessed in vivo in live
mice using echocardiographic imaging. Mice were anesthetized with inhaled isofluorane
(1.5-4%), hooked up to a heart rate monitor, and then Nair was used to remove the fur on
the thorax. Scanning was performed with a 40 MHz 704 scanhead on a Vevo 770
echocardiography machine (VisualSonics), and at least four images were stored for each
mouse. Each image contains 100 frames over the course of multiple heart beat cycles.
Images were transferred off the Vevo 770 machine and analyzed using Sante Dicom
Editor software (Santesoft LTD, Athens, Greece). Aortic diameter was measured at peak
tension, at which point the aorta has reaches its maximum diameter. At least three
measurements were made per session, which were then averaged to obtain the final
reported measurement. Aortic diameters were normalized to mouse weight, taken at the
same time as the echocardiographic measurements, to compensate for the mixed gender
groups used in the study.

Histology processing and analysis
Mice were anesthetized using freshly prepared 2.5% avertin, then the chest cavity
was opened to expose the heart. A 26 gauge needle was inserted into the left ventricle,
and the mouse was fully perfused with 5mL Dulbecco’s phosphate buffered saline,
followed by 5mL of 10% neutral buffered formalin. Following perfusion fixation, the
ascending aorta was exposed and dissected out of the mouse. Cuts were made proximal
to the aortic root at the heart and between the two carotid branches at the aortic arch. The
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right carotid artery was kept to orient the vessel. Tissue was left to fix in 10% neutral
buffered formalin, then subjected to a series of dehydrating washes in 50%, 70%, 95%,
and 100% ethanol, followed by incubation in histoclear before being embedded in
paraffin.
Paraffin blocks were sectioned into 5um sections, which were stained with
hematoxylin and eosin or with MOVAT pentachrome according to standard protocols.
Analysis was performed using ImageJ software. The color threshold tool was used to
designate and count pixels within the aortic wall that were black (elastin), blue
(proteoglycans), or red (muscle cells). Elastin breaks were quantitated by visual
inspection.

qPCR and Western blot analysis
After removal of the ascending aorta (see protocol above), tissue was snap frozen,
then homogenized using a Fisherbrand handheld tissue homogenizer in either Trizol
(RNA) or RIPA buffer (protein, see Chapter 2 for buffer composition). RNA and protein
were isolated and quantitative RT-PCR and Western blotting were performed according
to standard protocols (see Chapter 2 for detailed descriptions).

Contractility assays
Four week old mice were anesthetized with 2.5% avertin and the ascending
aortas were dissected out, measured and weighed, and mounted on wire triangles. The
mounted tissue was hooked up to an isometric force apparatus, then equilibrated and
stretched to 1.8g. Tissue was allowed to recover for 45 minutes following initial
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stretching. Physiological buffer was used during all recovery periods (118.5mM NaCl,
4.75mM KCl, 1.2mM MgSO4, 1.2mM KH2PO4, 24.9mM NaHCO3, 1.6mM CaCl2,
10.0mM D-glucose, pre-gassed with 95% O2/5% CO2 at 37°C). Rings were stimulated
four times with KCl (90mM) for 5 minutes each, separated by 5-minute recovery periods
in physiological buffer. Tissue was allowed to equilibrate for 45 minutes following the
last stimulation with KCl, then were stimulated once with 10mM phenylephrine for 5
minutes. Finally, tissues were snap frozen with clamps pre-cooled in liquid nitrogen and
stored at -80°C for possible future protein analysis.

Statistical analsyis
Kruskal-Wallis, a nonparametric statistical test suitable for comparing multiple
groups, was used for all multigroup comparisons. General p values reported indicate
significant differences between the means of all 9 groups (the KW statistic). Dunn’s
post-tests were performed to assess significant differences between Acta2+/- Myh11+/+
and Acta2+/- Myh11R247C/R247C groups as well as between Acta2-/- Myh11+/+ and Acta2-/Myh11R247C/R247C. No other pairs of groups were specifically compared.
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Figure 3.2. No aortic dilation in Acta2-/- Myh11R247C/R247C mice at 4 weeks of age. A)
The R247C allele does not affect the number of elastin layers layed down during
development in Acta2-/- mice. B,C) No significant difference in the aortic diameter at the
ascending (B) or root (C) level in any genotype of mice at 4 weeks of age.
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Results
Introduction of the Myh11 R247C mutation does not affect the developmental phenotype
of Acta2-/- mice
As described above, Acta2-/- mice have a developmental phenotype leading to
increased numbers of elastic lamellae in the aorta observable at all timepoints. The
homozygous addition of the R247C allele affected the number of elastic lamellae laid
down (Figure 3.2a). Additionally, at 4 weeks of age, there is no difference in the mean
diameter of the ascending aortas of any of the 9 genotypes (p=0.33), nor is any dilatation
observable at the aortic root (p=0.31) (Figure 3.2b,c).

Figure 3.3. Myh11 R247C allele modifies Acta2-/- aortic phenotype at 8 weeks of
age. A, B) By 8 weeks of age, Acta2-/- Myh11R247C/R247C mice show a trend towards
increased aortic diameter in the ascending aorta (A) and a significantly increased
aortic diameter at the aortic root (B).

Aortic dilatation becomes significant by 8 weeks of age in Acta2-/- Myh11R247C/R247Cmice
By 8 weeks of age, echocardiographic analysis shows a trend towards increasing
ascending aortic diameter with the addition of the R247C allele (p=0.07) (Figure 3.3a).
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Neither of the post-tests between pairs of genotypes showed a significant increase in
aortic diameter, however there is a trend towards increased aortic diameter with
homozygous addition of the Myh11 R247C gene on the Acta2+/- background. Similarly,
there is a dose dependent effect of the R247C allele on ascending aortic diameter on the
Acta2-/- background. At the level of the aortic root, there is a significant dilatation

Figure 3.4. Myh11 R247C allele increases Acta2-/- aortic diameter at 12 weeks of
age. A, B) By 12 weeks of age, Acta2-/- Myh11R247C/R247C mice show a significantly
increased aortic diameter at the level of both the ascending aorta (A) and the aortic
root (B) by echocardiography. C) No significant difference in medial area at 12
weeks of age. D) Histology measurements confirm increased diameter in Acta2+/Myh11R247C/R247C mice.
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present (p=0.01), and similarly the Acta2+/- Myh11 R247C/R247C aortas are enlarged
compared with Acta2+/- Myh11+/+ aortas (not significant) while there is a gene dose
effect with the addition of the R247C allele to the Acta2-/- mice (p<0.05) (Figure 3.3b).

Figure 3.5. Myh11 R247C allele does not affect medial degeneration in Acta2-/aortas at 12 weeks of age. A) Representative aortic sections stained with MOVAT
pentachrome from each of the 9 genotypes at 12 weeks of age. B, C) Analysis of
elastin fragmentation (B) and proteoglycan deposition (C) shows that the R247C
allele does not impact medial degeneration at 12 weeks of age.

By 12 weeks of age, aortic dilatation becomes significant and medial degeneration
begins
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By 12 weeks of age, the changes in aortic diameter across all genotypes becomes
significant at the level of both the ascending aorta (p=0.01) and the aortic root (p=0.01)
(Figure 3.4a,b). Again, the trend suggests that the homozygous R247C allele combined
with loss of one Acta2 allele (Acta2+/-) elicits aneurysm formation. In constrast, there is
a dose-dependent effect on the Acta2-/- background. These results therefore confirm that
over time the modifying effect of the R247C allele on aortic phenotype remains similar,
but becomes more statistically significant.
Histologic analysis of the 12 week aortas shows very limited effects of
introduction of the R247C allele on medial thickening, proteoglycan deposition, or
elastin fragmentation (Figure 3.4c, Figure 3.5a,b,c). The Acta2-/- aortas, regardless of
the R247C gene dose, have increased medial area, increased percent area of
proteoglycans, and increased numbers of elastin breaks compared to wild-type or
Myh11R247C/R247C. However, there are no significant differences between groups
containing different numbers of R247C alleles on the same Acta2 background.

At 6 months of age, both aortic dilatation and medial degeneration are significantly
greater in Acta2-/-Myh11R247C/R247C aortas
As at 8 and 12 weeks of age, at 6 months of age there is a significant dose
dependent effect of the R247C allele on the aortic root and ascending aortic diameters of
Acta2-/- mice (Figure 3.6a,b). By 6 months, we begin to see a similar dose dependent
effect in the Acta2+/- background, suggesting that perhaps as the mice age a heterozygous
R247C allele might also induce disease on this background. Again both ascending
(p=0.02) and root (p=0.02) diameters are significantly different between groups.
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Figure 3.6. Myh11 R247C allele increases Acta2-/- aortic diameter at 24 weeks of age.
A, B) At 24weeks of age, Acta2-/- Myh11R247C/R247C mice show a significantly increased
aortic diameter at the level of both the ascending aorta (A) and the aortic root (B) by
echocardiography. C, D) Medial area (C) and histologic measurements of aortic diameter
(D) reflect the same trend as echocardiographic findings.
In contrast to earlier analyses, however, proteoglycan deposition is increased in a
dose-dependent manner with the addition of the R247C allele on the Acta2-/- background
(Figure 3.7a,c). Similarly, the Acta2+/-Myh11R247C/R247C aortas have increased
proteoglycan deposition compared with Acta2+/- mice with zero or one copies of the
R247C allele. However, elastin breaks are not increased in Acta2+/-Myh11R247C/R247C
aortas, or in Acta2-/-Myh11R247C/+ aortas, suggesting either that the R247C allele may
preferentially increase proteoglycan deposition over elastin fragmentation, or that
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proteoglycan deposition generally precedes elastin fragmentation in the disease process
(Figure 3.7b). There is a trend towards increased medial area as the aortic diameter
increases, but the results are not significant (Figure 3.6c).

Figure 3.7. Myh11 R247C allele increases proteoglycan deposition in Acta2-/aortas at 24 weeks of age. A) Representative aortic sections stained with MOVAT
pentachrome from each of the 9 genotypes at 24weeks of age. B, C) Analysis of
elastin fragmentation (B) and proteoglycan deposition (C) shows that the R247C
allele increases medial degeneration in Acta2-/- aortas but only impacts proteoglycan
deposition in Acta2+/- aortas.

Addition of the R247C allele does not further decrease contractility in the Acta2+/- or
Acta2-/- aortas
We hypothesized that the R247C allele would further decrease contractility in
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Acta2+/- and Acta2-/- aortas, and that a threshold level of decreased contractility could be
established beyond which aortic disease results. Contractility assays were performed to
determine the role of decreased contractility in the modifying effect of the Myh11
R247C alteration. Surprisingly the presence of the R247C allele had no effect on the
contractility of either Acta2+/- or Acta2-/- aortas in response to either KCl or
phenylephrine (Figure 3.8). These results contradict our hypothesis, and suggest that an
alternative mechanism distinct from decreased contractility underlies the enhanced aortic
aneurysm and pathology apparent with the addition of the R247C allele.

Figure 3.8 Myh11 R247C allele does not affect contractility of Acta2-/- aortas. The
addition of the R247C allele does not impact aortic contractility in response to either
KCl or phenylephrine (PE) in Acta2+/- or Acta2-/- mice.
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Discussion
The addition of the R247C allele worsens the aortic disease phenotype in Acta2-/mice and induces aortic disease in Acta2+/- mice. By 8 weeks of age, aortic diameter is
increased in mice of either Acta2 genotype carrying homozygous R247C alleles
compared with Myh11+/+ littermates. As the mice age, the aortic diameter progressively
increases. Therefore, the R247C allele both accelerates the onset of aortic disease and
increases its severity.
The data presented speak to two distinct clinically relevant patient populations
whose disease has previously been unexplained. First, the Acta2+/- Myh11R247C/R247C mice
are analogous to young patients who present with TAAD with no family history, no
environmental risk factors for disease, and no identifiable de novo mutation in the
previously characterized disease-causing genes [86]. Here, heterozygous loss of Acta2
and the Myh11 R247C missense mutation, which independently do not cause any
pathology, lead to disease when they co-occur. These results suggest that patients could
inherit multiple rare genetic variants that cumulatively cause disease, while each parent
carries a subset of variants that are insufficient to provoke a phenotype.
Furthermore, clinical histories of families with TAAD reveal significant
variability in the age of onset, and even in the severity of the clinical presentation,
between family members who carry identical disease causing mutations [87]. The earlier
onset and increased severity of disease in Acta2-/- Myh11R247C/R247C mice suggests that
rare variants that differ between affected family members may drive the clinical
variability, promoting more severe disease in a subset of family members.
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Initially, we hypothesized that the modifying effect of the R247C allele would be
due to decreased aortic contractility, and therefore we expected to see a synergistic loss
of contractility at early timepoints in the genotypes that later developed more disease.
However, the presence of the R247C allele had no effect on the contractility of Acta2+/or Acta2-/- aortas, suggesting that the mechanism underlying increased disease in mice
carrying that allele is not additive contractile dysfunction. Since loss of force generation
in the myosin motor is the most direct phenotypic outcome of the R247C mutation, this
result was surprising. However, the cellular data presented in Chapter 2 suggest that
downstream signaling effects of this loss of myosin motor function have a profound
effect on SMC phenotype. Plausibly, although aortic contractility itself is not affected by
the combination of the Myh11 R247C allele and the loss of Acta2, distinct downstream
signaling driven by each genetic change combines to provoke a more severe disease.
Despite evidence of significant aortic enlargement at 8 weeks of age, the
expected R247C-induced increase in medial degeneration does not become significant
until 6 months of age. Proteoglycan deposition is increased in Acta2-/- Myh11R247C/R247C
mice compared with Acta2-/- Myh11+/+mice and is also significantly increased in Acta2+/Myh11R247C/R247C mice than in Acta2+/- Myh11+/+ mice. However, elastin fragmentation is
only affected by the R247C allele on the Acta2-/- background. These results taken
together suggest a disease progression in this particular mouse model whereby aortic
dilatation is the initial observable effect, followed by proteoglycan deposition, and
eventually by elastin fragmentation. Previous data shows that increased matrix
metalloproteinase (MMP) activity drives elastin fragmentation in multiple aneurysm
models, and unpublished data from our lab indicates that signaling by glycogen synthase
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kinase 3β (GSK3β ) drives expression of proteoglycans in SMCs [50]. However the
mechanistic links between aortic dilatation and GSK3β signaling or between GSK3β
signaling and MMP activity are incompletely established. Future work on this mouse
model will examine the activity of MMPs and will establish patterns of signaling
changes including potential increases in GSK3β activation or in angiotensin receptor
type 1-driven signaling.
In summary, the data show that Myh11 R247C is a modifier allele for aortic
disease: it can cause disease in conjunction with another benign genetic variant
(heterozygous loss of Acta2), and it can accelerate disease progression in a genetic
model of aneurysm formation (homozygous loss of Acta2).
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Chapter 4: 16p13 Duplications Lead to Increased Contractile Protein Turnover
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Introduction
To identify novel genetic variants associated with sporadic TAAD, DNA samples
isolated from spit or blood samples from approximately 800 Caucasian TAAD patients
without a family history of disease were subjected to a copy-number variant (CNV)
screen, along with 4500 control DNA samples. Initial screening was performed on an
Illumina whole genome SNP array, and statistically interesting results were pulled out
using two separate CNV algorithms. Data were confirmed using specific quantitative
PCR based assays, and further replicated using an additional patient cohort. This
analysis identified a recurrent CNV, duplications at the 16p13.1 chromosomal locus, that
is associated with thoracic aortic disease [88]. Low copy repeats are prevalent in this
region of the genome, making it a hotspot for nonhomologous recombination and
therefore a common site of CNVs. Previous studies had implicated both deletions and
duplications in this locus in the pathogenesis of multiple different neuropsychiatric
disorders, including schizophrenia and autism [89-91]. However, the genetic data from
these earlier studies indicated a 2- to 3-fold enrichment of these CNVs in these
neuropsychiatric patients compared with unaffected controls. Our data showed a
reproducible 11-fold enrichment of 16p13.1 duplications in patients with TAAD, and in
fact this specific CNV was present in 1% of all patients with TAAD compared to less
that 0.1% of the general population. Therefore, 16p13.1 duplications are the most
common genetic risk factor for TAAD identified to date.
Patients carrying the 16p13.1 duplications were more likely to have a younger
age of disease presentation. Uniformly, these patients had hypertension and presented
with dissections without signs of prior aortic enlargement. Due to the high density of low
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copy repeats in the 16p13.1 region, unrelated patients had distinct break points marking
the ends of their duplicated regions. However, a common region containing nine genes
was duplicated in every patient identified with 16p13.1 duplication. Directly in the
center of the commonly duplicated region lies MYH11. Due to our previous knowledge
of a link between MYH11 and vascular disease, we hypothesized that MYH11 is the gene
that causes increased risk of TAAD in people with 16p13.1 duplications.
Little is known about how gene duplications lead to human disease. In
particular, the molecular mechanisms linking three copies of MYH11 with a
predisposition for aortic dissection are not immediately apparent. Because the additional
copy of the MYH11 gene should increase the expression and production of myosin
heavy chain, we focused on possible pathways that would link this overexpression to the
disease. As described in Chapter 1, the MYH11 gene encodes four distinct transcripts
leading to four isoforms of the smooth muscle myosin heavy chain protein, of which two
are expressed in the aorta [92]. Transgenic mouse models overexpressing each of those
two isoforms were previously generated and characterized. Despite evidence of
successful transgene expression from the use of a tagged myosin protein, neither
transgenic expression of SM1 nor SM2 altered the ratio between the two isoforms in
aortic tissue (Figure 4.1a). However, both transgenic models did result in profound
effects on the contractility of the aorta: the SM1 model had increased aortic contractility
while the SM2 model had decreased aortic contractility (Figure4.1b,c) [33]. These
results suggest that the overexpression of myosin leads to selective degradation that
normalizes the total amount and isoform ratio of myosin in the cell. Simultaneously, the
changes in contractility support the hypothesis that overexpression of myosin affects
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smooth muscle cell phenotype in a similar manner to other causes of genetically
triggered aortic disease.

Figure 4.1 Transgenic overexpression of myosin isoforms alters aortic
contractility. A) Transgenic overexpression of either SM1 or SM2 does not affect the
ratio of SM1:SM2 or the total level of myosin protein. B) SM1 transgenic mice have
increased aortic contractility. C) SM2 transgenic mice have decreased aortic
contractility. Reprinted with permission from Expression and function of COOHterminal myosin heavy chain isoforms in mouse smooth muscle. Martin AF, Bhatti S,
Pyne-Geithman GJ, Farjah M, Manaves V, Walker L, Franks R, Strauch AR, Paul RJ.
Am J Cell Physiol. 2007.
Myosin heavy chain molecules require a specific molecular chaperone to ensure
proper protein folding; folding of myosin is critical as monomers of myosin interact with
each other to form first dimers, then filaments. Increased expression of myosin would
therefore reduce access of individual molecules to the required chaperone protein,
potentially resulting in a pool misfolded monomers that could have outsized effects on
filament formation. The myosin-specific chaperone, first described in the nematode
worm Caenhorabditis elegans (C. elegans), is known as Unc45 [93]. Mammalian
organisms have two Unc45 genes, encoding two distinct isoforms of the chaperone
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called Unc45a and Unc45b [94]. Unc45b is specifically expressed in striated muscle and
acts as the chaperone for cardiac and skeletal muscle myosins. Unc45a is ubiquitously
expressed, and is the canonical chaperone for nonmuscle and smooth muscle myosins.
Early work performed on this chaperone in the C. elegans model indicated that the ratio
of expression of myosin to Unc45 is tightly regulated. Worms engineered to either
underexpress or overexpress Unc45 both showed accelerated degradation of myosin
protein via the ubiquitin-proteasome system (Figure 4.2a,b,c) [95].

Figure 4.2 Unc45 overexpression drives myosin degradation in C. elegans. A)
Reduced numbers of myosin filaments in C. elegans muscle cells with Unc45
overexpression. B) Loss (dark grey bars) or overexpression (white bars) of Unc45
reduces accumulation of all isoforms of myosin heavy chain in C. elegans. C) Model
showing the requirement of Unc45 for stable assembly of myosin filaments. Reprinted
with permission from The UNC-45 chaperone mediates sarcomere assembly through
myosin degradation in Caenorhabditis elegans. Landsverk ML, Li S, Hutagalung AH,
Najafov A, Hoppe T, Barral JM, Epstein HF. J. Cell Biol. 2007.
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Therefore, studies on Unc45 suggest a potential mechanism by which
overexpression of MYH11 in 16p13.1 duplication patients could cause disease:
paradoxically, too much myosin expressed could drive degradation of myosin protein
and leave the SMCs unable to properly contract.

Materials and Methods
Protocols for vascular SMC explant from aortic tissue, cell culture, RNA
isolation from cells or tissue and quantitative PCR, protein isolation from cells or tissue
and Western blotting, and immunofluorescent cellular staining are described in detail in
Chapter 2. For additional antibodies used in this chapter see Table 4.1.
Antigen

Company

Species

Uses

LC3

Novus Biologicals

Rabbit

WB

p62

Sigma

Rabbit

WB

Phospho-AMPK

Cell Signaling Technology

Rabbit

WB

AMPK

Cell Signaling Technology

Rabbit

WB

Phospho-ACC

Cell Signaling Technology

Rabbit

WB

ACC

Cell Signaling Technology

Rabbit

WB

Phopho-p70S6K

Cell Signaling Technology

Rabbit

WB

p70S6K

Cell Signaling Technology

Rabbit

WB

Phospho-S6

Cell Signaling Technology

Rabbit

WB

Phopho-PERK

Cell Signaling Technology

Rabbit

WB

PERK

Cell Signaling Technology

Rabbit

WB

Phospho-EIF2α

Cell Signaling Technology

Rabbit

WB

EIF2α

Cell Signaling Technology

Rabbit

WB

Grp94

Enzo Life Sciences

Rabbit

WB

Grp78

Enzo Life Sciences

Rabbit

WB
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Erp72

Enzo Life Sciences

Rabbit

WB

MLC20

ECM Biosciences

Mouse

IF

MLC20

Cell Signaling Technology

Rabbit

WB

Phospho-MLC20 (Ser19)

Cell Signaling Technology

Rabbit

WB

Table 4.1 Antibodies used in Chapter 4.

Radiolabeled pulse-chase assay
Confluent cells were seeded into 35mm dishes (100,000 cells per dish) and
allowed to attach overnight. Media was changed to 1% serum containing medium for 24
hours before being switched to pulse media (1% serum containing media plus 0.1uCi/mL
14

C labeled phenylalanine). At specified timepoints throughout the pulse period, media

was removed, and cells were lysed in 1mL 10% trichloroacetic acid and stored at 4°C
until the end of the experiment. At the end of the pulse period (48 hours), the media were
changed on remaining plates to chase media (1% serum containing media plus 2mM
excess unlabeled phenylalanine). At specified timepoints during the chase period, a
500uL aliquot of media was removed and combined with 500uL of 20% trichloroacetic
acid. These aliquots were also stored at 4°C until the end of the experiment. At the end
of the experiment, all lysates were combined with scintillation fluid and analyzed on a
1900TR liquid scintillation analyzer (Packard Instruments). Protein synthesis rates were
calculated using the incorporation of 14C into cellular protein over the pulse period,
while protein degradation rates were calculated using the rate of 14C release into the
media over the chase period as measured by dpm [163].
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Infection with RFP-GFP-LC3 lentivirus
The RFP-GFP-LC3 lentivirus and a control lentivirus were both generously
given to us by Joseph Hill, M.D., Ph.D., and his lab at University of Texas Southwestern
Medical Center. Cells were seeded as for other immunofluorescence protocols, and after
being allowed to incubate overnight, cells were treated with 1% serum containing media
supplemented with 1uL/mL polybrene and viral titers at a multiplicity of infection of 5,
determined through initial dose-dependent experiments to find the optimal multiplicity
of infection. After 72 hours of incubation with the virus, cells were fixed in 4%
paraformaldehyde as described previously, and coverslips were mounted in Vectashield
mounting media with a DAPI counterstain.

Collagen contraction assays
Cells were separated into 250,000 cell aliquots and seeded within a matrix of
type I collagen from rat tail (BD Biosciences). The collagen mixture was prepared
according to the manufacturer’s specifications at a final concentration of 1mg/mL
collagen. Gels were allowed to polymerize at room temperature for at least one hour,
then were immediately treated with 1% serum containing media with or without the
addition of 1mg/mL 4-phenylbutyric acid. Gels were allowed to incubate for 5 days to
accumulate tension, and then were released from attachment to the cell culture plastic to
induce contraction. Gels were photographed 10 minutes after release, and measurements
were performed using ImageJ software [164].

Calcium imaging
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Cells were seeded onto 10mm coverslips at a density of 5,000 cells per coverslip
and allowed to attach overnight. Cells were then incubated in 1% serum media with or
without the addition of 1mg/mL 4-phenylbutyric acid for 24 hours. Coverslips were pretreated with 4uM Fura-2AM (Teflabs) for 30 minutes at 37°C, then transferred to
calcium free ECS buffer (140 mM NaCl, 5 mM KCl, 1mM MgCl2, 10 mM HEPES, 10
Glucose (pH 7.4)) for the remainder of the experiment. Coverslips were mounted for
viewing on a Nikon TE200 microscope, and imaging was performed with Incytim2
software. Measurements were taken at 340nm and 380nm, and the intensity ratio was
used to determine calcium levels. This provides an internal control so that the success of
dye-loading does not affect the concentration readouts. Baseline measurements were
taken for one minute, then 1uM thapsigargin was added to the buffer. Measurements of
cytoplasmic calcium continued out to six minutes to allow partial recovery from the
thapsigargin [165].

Results
Increased protein turnover in systems of myosin overexpression
Initial characterization was performed using frozen aortic tissue samples from
patients with 16p13 duplications. Compared with control tissue samples, 16p13
duplication patient tissue showed a significant increase in expression of MYH11.
Surprisingly, there was a similar increase in expression of other contractile proteins
(ACTA2 and CNN1) (Figure 4.3a). However, there was no concomitant increase in the
accumulation of SM-MHC protein level, or of actin or calponin protein levels (Figure
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4.3b). These results suggested that there may be translational control or increased
degradation of the proteins..
A specific chaperone called Unc45a helps to fold the smooth muscle and
nonmuscle myosin heavy chain isoforms. In 16p13 duplication patient tissue, both
mRNA expression and protein accumulation of Unc45a was significantly decreased
compared with control tissue (Figure 4.3c,d). However, ectopic expression of Unc45b,
typically seen only in cardiac and skeletal muscled cells, was observed in the tissue
(Figure 4.3d).

Figure 4.3 Changes in contractile gene expression and Unc45 isoform expression
in tissue from 16p13 duplication patients. A) Increased expression of contractile
genes in frozen tissue from patients with 16p13 duplication. B) No change in
contractile protein levels in aortic tissue with 16p13 duplication. C,D) Reduced
expression of Unc45a and ectopic expression of Unc45b in patients with 16p13
duplication.
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The mouse SM1 cell model of myosin overexpression shows the same phenotype
as the 16p13 duplication tissue: increased contractile gene expression, with no change in
contractile protein levels compared with wild-type cells, accompanied by decreased
Unc45a mRNA expression and ectopic expression of Unc45b (Figure 4.4a,b,c,d). These
results suggest that the SM1 cells are a good model to study the cellular changes
associated with overexpression of Myh11.

Figure 4.4 SM1 transgenic cells recapitulate phenotype of patient tissue. A) No
change in contractile protein levels in cultured SM1 SMCs. B) Increased expression of
contractile genes in culture SM1 SMCs. C,D) Reduced expression of Unc45a and ectopic
expression of Unc45b in SM1 SMCs.
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Because increased expression at the mRNA but not the protein level suggested a
possible phenotype of increased protein turnover, we blocked elongation using
cycloheximide and followed protein degradation over time. Cycloheximide is a protein
translation inhibitor that is well tolerated by SMCs and does not cause cell death
[96,97]. In wild-type (abbreviated here as NTG for nontransgenic) cells, the contractile
proteins remain highly stable up to 36 hours after protein translation is inhibited (Figure
4.5a). These results are consistent with previous reports about the half-life of contractile
proteins in all muscle cells [98,99]. However, in SM1 SMCs, contractile protein levels
begin to decay by 24 hours. Because cycloheximide does disrupt the translation system,
we used a second pulse-chase assay to more globally assess total protein synthesis and
degradation. Phenylalanine labeled with 14C was introduced into the culture media, and
the cells incorporate it into new cellular proteins. Protein synthesis can be assessed by
looking at accumulation of 14C in the cellular protein lysates, while degradation can be
assessed by the release of 14C into the media during the chase period [163]. Both protein
synthesis and degradation were significantly increased in SM1 cells compared with NTG
cells (Figure 4.5b,c). This result is consistent with a phenotype of increased protein
turnover.
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Figure 4.5 Increased protein turnover in SM1 SMCs. A) Treatment with
cycloheximide shows accelerated degradation of contractile proteins in SM1 cells,
quantified to the right. B,C) Radioactive pulse-chase assay shows increased global
protein synthesis (B) and degradation (C) in SM1 SMCs.

Protein turnover in SM1 cells is driven by autophagy and not proteasomal degradation
SM1 and NTG SMCs were treated with a proteasome inhibitor, bortezomib, to
assess whether the ubiquitin-proteasome system were responsible for the observed
increase in protein degradation. However, treatment with bortezomib does not lead to
increased accumulation of contractile proteins in SM1 SMCs; rather, the levels of SMMHC protein are decreased after 24 hours of bortezomib treatment (Figure 4.6a). To
confirm that the decreased protein levels were due to changes in protein degradation
rather than changes in mRNA expression, we assessed gene expression of contractile
genes during bortezomib treatment. In NTG cells, by 4 hours after the initiation of
bortezomib treatment expression of Acta2, Cnn1, and Myh11 all decrease significantly
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(Figure 4.6b). Despite this decrease in expression, there is no change in protein level of
SM-MHC, SM-actin, or calponin, suggesting that the proteasome may be responsible for
regulating contractile protein turnover in NTG cells. By contrast, in SM1 cells,
expression of contractile genes actually increases at early time points of bortezomib
treatment, and does not decrease up to 24 hours of treatment. Taken together with the
decrease in protein levels, these results suggest that the ubiquitin-proteasome system is
not responsible for degrading contractile proteins in SM1 cells.

Figure 4.6 Autophagy, not the proteasome, drives protein degradation in SM1
SMCs. A) Treatment with the proteasome inhibitor bortezomib does not induce
contractile protein accumulation in SM1 SMCs. B) Bortezomib decreases contractile
gene expression by qPCR in NTG cells, but not in SM1 cells. C) Treatment with
lysosomal inhibitors pepstatin A and e64d causes accumulation of contractile proteins in
SM1 but not NTG cells. D) Lysosomal inhibitor treatment decreases contractile gene
expression (assessed by qPCR) in both NTG and SM1 cells.

83

Next we examined whether the other protein degradation pathway, autophagy,
was responsible for the degradation of contractile proteins in SM1 cells by using a
combination of the lysosomal inhibitors pepstatin A and E64d to block autophagy.
Unlike the results with bortezomib, lysosomal inhibitors lead to an accumulation of
contractile proteins in SM1 SMCs over 36 hours of treatment, but not in NTG SMCs,
supporting that autophagy is involved in the degradation of these proteins (Figure 4.6c).
Message levels for of all three contractile genes significantly decreases by 12 hours after
initiation of lysosomal inhibitor treatment in both genotypes (Figure 4.6d).
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Figure 4.7 Increased autophagy markers in SM1 cells. A) Immunofluorescence with
an RFP-GFP-LC3 lentivirus shows increased autophagic flux in SM1 cells by increases in
both autophagosomes (yellow dots) and autolysosomes (red dots). B) Quantitation of
immunofluorescent images confirms increased autophagy in SM1 cells. C) Western
blotting shows decreased accumulation of p62 and increased processing of LC3 in SM1
cells.
To further assess if autophagy is increased in SM1 cells, we looked by
immunoblot analysis at markers of autophagic activity. LC3 is a key protein involved in
the autophagic pathway; as autophagy progesses, LC3 undergoes proteolysis, then
lipidation and associates with the autophagosomal membrane [100]. Despite being
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larger, lipidated LC3, or LC3 II, therefore migrates faster on a Western blot than LC3 I
due to increased hydrophobicity. The LC3 II to LC3 I ratio is significantly increased in
SM1 compared with NTG cells (Figure 4.7c). Likewise, p62 is a protein known to be
degraded by autophagy, and decreased levels of p62, as seen in SM1 compared with
NTG cells, are the result of increased autophagy (Figure 4.7c) [101]. Finally, we used
an RFP-GFP-LC3 expressing lentivirus to assess autophagic flux in the cells. At early
stages of autophagy, LC3 is tagged with both RFP and GFP. During initial
autophagosome formation, LC3 staining becomes punctate and the dots appear yellow.
As the autophagosome fuses with the lysosome to form an autolysosome, the pH of the
compartment decreases and GFP is destabilized, leaving only RFP expression, changing
the LC3 fluorescence to red. Based on quantitation of puncta in fixed cells, SM1 cells
have significantly more autophagosomes and autolysosomes than NTG cells, suggesting
an increase in autophagic flux (Figure 4.7a,b).

mTOR signaling and autophagy in SM1 cells
The most commonly studied cellular pathway leading to increased autophagy is a
decrease in mammalian target of rapamycin (mTOR) signaling [102]. The current data in
the field indicate that AMP-associated protein kinase (AMPK) and mTOR are the
primary regulators of autophagy initiation, with AMPK as an activator of the process
and mTOR as an inhibitor [103]. The two kinases similarly have been shown to inhibit
each other [104]. Thus, under normal conditions when nutrient levels are high, AMPK is
not activated, and mTOR remains active to drive protein synthesis. Under conditions of
starvation or cellular stress, AMPK becomes activated, mTOR gets turned off, protein
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synthesis decreases and autophagy goes up in an effort to conserve energy. There is a
moderate increase in SM1 cells in phosphorylation of ACC, the downstream target of
AMPK (Figure 4.8a). However, SM1 cells also have increased global levels of protein
synthesis, and signaling downstream of mTOR, indicated by the phosphorylation of
p70S6 kinase and of the ribosomal protein S6, was dramatically increased in SM1 cells
than in NTG cells (Figure 4.8b). Therefore, an alternative cellular pathway must be

Figure 4.8 Altered signaling pathways in SM1 cells. A) Increased AMPK-related
signaling in SM1 cells. B) Increased mTOR-driven signaling in SM1 cells. C)
Increased accumulation of ER stress markers in SM1 cells.
driving autophagy in the SM1 cells.

ER stress in SM1 cells
Another cellular process that has been linked with autophagy is the induction of
endoplasmic reticulum (ER) stress pathways [105-106]. Nascently translated proteins are
processed in either the cytoplasm or the ER for proper protein folding and posttranslational modifications. However, if the system is slowed down for any reason, the
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ER sends out signals to drive transcription and translation of supporting proteins, shut
down any nonessential protein synthesis, and induce autophagy. Because of the increase
in global protein synthesis, as well as the imbalance in expression of SM-MHC and its
Unc45 chaperone, we hypothesized that ER stress might be increased in the SM1 cells,
and could potentially be driving autophagy. Phosphorylation of PERK and its
downstream target eIF2α indicates activation of one of the three major signaling
pathways initiated by ER stress [107]. Grp78, Grp94, and Erp72 are all chaperone
proteins that are upregulated to help relieve ER stress [108]. All markers assessed were
upregulated in SM1 cells compared with NTG cells (Figure 4.8c).

Increased contraction in SM1 cells
Intriguingly, the SM1 transgenic mice have increased aortic contractility in vivo.
Although the contractile proteins are clearly turned over more rapidly, it is unclear what
effect the increased turnover has on filament formation and stability. To assess filament
architecture, we first used immunofluorescence to visualize the filaments in
paraformaldehyde fixed cells. Staining for either the myosin regulatory light chain or αactin reveals thin, stretched out filaments across the cell body of NTG SMCs (Figure
4.9a). However, the filament structure in SM1 cells appears less organized and the
staining appears brighter. For further insight, we performed an ultracentrifugation based
assay to separate polymerized from unpolymerized actin. There was no difference in the
ratio of polymerized to unpolymerized actin between SM1 and NTG cells (Figure 4.9b).
These results suggest that while filaments could potentially be less stable in SM1 cells,
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the actual number of filaments present in the cell at any given time is comparable to the
NTG SMCs.
To further probe the question of contractility, we use a collagen gel contraction
assay. After incubation in 1% serum media for four days, the gels were released and
allowed to contract. Gels populated with SM1 cells contracted significantly more than
gels populated with NTG cells (Figure 4.9d).

Figure 4.9 Increased contractility of SM1 SMCs. A) Immunofluorescence showing
contractile filament formation in SM1 cells. B) Ultracentrifugation assay shows similar
ratios of F/G actin in NTG and SM1 cells. C) Western blotting confirms increased
phosphorylation of myosin regulatory light chain in SM1 cells. D) Collagen gel
contraction assays show increased contraction of SM1 SMCs.

89

Since increased contraction does not seem to be due to increased numbers of
contractile filaments, we next asked whether signaling driving smooth muscle
contraction was increased. As described in Chapter 1, phosphorylation of the myosin
light chain is the primary determinant of SMC contractility [14]. SM1 cells have
significantly more phosphorylated myosin light chain at residue serine 19, indicating that
alterations in signaling pathways may be driving the observed increase in contractility
(Figure 4.9c).

Calcium signaling changes in SM1 cells
Increases in intracellular calcium ion concentration lead to increased activity of
the myosin light chain kinase, and thus increased phosphorylation of the myosin light
chain. Additionally, one of the known effects of ER stress is the release of calcium ions
from stores within the ER [109]. Therefore, we sought to determine if baseline cytosolic
calcium concentrations were increased in SM1 cells and, if so, would the cells respond
aberrantly to thapsigargin, a drug that inhibits calcium reuptake into the ER. After fura2am loading, cells were placed in calcium free buffer and imaged over time and after
addition of thapsigargin. SM1 cells did have a higher baseline intracellular calcium
concentration than NTG cells, and thapsigargin treatment also induced a faster response,
but the amplitude of the response was reduced (Figure 4.10a,b,c,d). These changes are
consistent with increased release of calcium from ER stores at baseline.
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Figure 4.10 Changes in calcium in SM1 SMCs. A) Average baseline cytosolic calcium
levels are increased in SM1 cells (red bar). Treatment with 4-pba (green bar) rescues the
increased calcium. B) Average percent increase in cytosolic calcium after thapsigargin
treatment is lowest in untreated SM1 cells (red bar), but 4-pba treatment rescues the effect
(green bar). C) Representative calcium trace showing the differential response of
untreated SM1 cells compared with NTG cells and SM1 cells treated with 4-PBA. Black
arrows indicate the time of thapsigargin addition. D) SM1 cells reach the peak calcium
concentration after thapsigargin administration faster than NTG cells, but this change is
rescued by treatment with 4-PBA.
4-phenylbutyric acid reduces autophagy and normalizes calcium signaling in SM1 cells
A small molecule chaperone compound, 4-phenylbutyric acid (4-PBA), has been
shown to relieve ER stress-related phenotypes in a number of systems [110-112]. In
SM1 cells, treatment with 4-PBA reduces the number of autophagosomes, suggesting
that autophagy in SM1 cells is, in fact, downstream of ER stress (Figure 4.11a).
Western blotting shows decreased LC3 processing in SM1 cells after treatment with 4-
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PBA, further supporting the hypothesis that ER stress leads to autophagy in these cells
(Figure 4.11b). Treatment of SM1 cells with 4-PBA also normalizes the intracellular
calcium ion concentrations and response to thapsigargin, yet the compound had no effect
on calcium in NTG cells (Figure 4.10a,b,c,d).

Figure 4.11 Treatment with 4-PBA reduces autophagy in SM1 cells. A) Treatment
with 4-PBA decreases the number of autophagosomes and autolysosomes present in SM1
cells infected with RFP-GFP-LC3 lentivirus. B) Western blotting confirms a decrease in
LC3 processing with treatment of 4-PBA, particularly in SM1 cells.
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Discussion
SMCs overexpressing myosin heavy chain have a unique phenotype
characterized by increased protein turnover of contractile proteins in conjunction with
increased cellular contractility. In frozen aortic tissue from patients with 16p13.1
duplications, as well as in SM1 transgenic mouse SMCs, contractile genes, including
MYH11 but also ACTA2 and CNN1, are expressed at higher levels than in wild-type
tissue or cells. However, in both cases, there is no corresponding increase in protein
levels of these contractile proteins. In the SM1 SMCs, analysis using cycloheximide or
radiolabeled amino acids confirms a global increase protein turnover, with both protein
synthesis and protein degradation occurring more rapidly in SM1 than in NTG cells.
Surprisingly, the increased protein degradation seen in SM1 cells is not driven by
the ubiquitin-proteasome system. Although previous work in C. elegans indicated that
any alteration in the ratio of Unc45 to myosin heavy chain expression led to
ubiquitination and degradation of myosin heavy chain [95], treatment with a proteasome
inhibitor did not induce accumulation of contractile proteins in SM1 cells. Instead,
autophagy is responsible for the protein turnover. Autophagy is a process of nonspecific,
bulk protein degradation that occurs as a protective measure in times of cellular stress.
Autophagy literally translates as “self eating” in Greek; the process involves turning
over proteins and cellular organelles to release nutrients and amino acids for reuse in
more essential cellular processes [113]. All cells have a low but constant level of
autophagic degradation, but autophagy is induced during various types of cellular stress
including nutrient deprivation or organelle damage. Briefly, signaling events that initiate
autophagy lead to the formation of a double-membrane vesicle known as an
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autophagosome engulfing the product to be turned over. Once formed, the
autophagosome fuses with a lysosome, and the acidic pH along with the variety of
proteolytic enzymes inside the compartment digest the cargo. The breakdown products
are released back into the cytosol [114,115]. Unregulated autophagy has previously been
associated with a number of human diseases including cancer and neurodegenerative
diseases [116-119].
The most well-characterized mechanism driving autophagy induction is
inhibition of mTOR: in fact, activated mTOR signaling inhibits autophagy induction via
a direct interaction between mTOR and Atg1, one of the initiators of the autophagy
cascade [102,103]. AMPK also directly interacts with Atg1, and opposes the activity to
mTOR to initiate autophagy when reserves of ATP are depleted [103]. However, in SM1
cells mTOR-driven signaling is actually increased, not decreased, so an alternative
mechanism must be driving autophagy. Specifically, the results presented suggest that
ER stress activation leads to autophagy. Until recently, mTOR activation and autophagy
were thought to mutually antagonize each other. Signals of nutrient deprivation induce
autophagy and downregulate mTOR, while signals of satiety downregulate autophagy
and induce protein synthesis via mTOR activation. Accumulated data now suggest that
mTOR activity and autophagy can coexist, and in fact may mutually reinforce each other
[120,121]. Certain free amino acids (specifically leucine and other branched chain amino
acids) are a potent activator of mTOR signaling via the small G protein Rag, and
autophagy generates free amino acids in localized areas of the cell by chewing up
cellular proteins [122-124]. A recent study proposed that a protein complex called
Ragulator after the Rag G-proteins couples autophagy to localized mTOR activation in a

94

feedback loop [123]. This model explains why the activated mTOR does not in turn
inhibit autophagy: the discrete localization within these complexes prevents mTOR from
interacting with and inhibiting Atg1 [125,126]. Similar pathways may be occurring in
SM1 cells, allowing mTOR to be active and driving further protein synthesis that causes
more ER stress, leading to more autophagy and more mTOR activation.

Figure 4.12 Model of cellular pathways in SM1 cells. Illustration shows
interactions between pathways and phenotypes identified in SM1 cells.
Here, the discussion of ER stress refers more specifically to the unfolded protein
response, a pathway activated by the accumulation of unfolded proteins in the
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endoplasmic reticulum as the protein folding machinery becomes overwhelmed. Three
transmembrane proteins lying on the ER membrane transduce the stress signal resulting
from accumulation of unfolded proteins: Atf6, Ire1, and PERK, which in turn activate a
number of signaling cascades leading to the redirection of cellular energy towards
resolving ER stress [107]. Specific downstream effects of these ER stress pathways
include increased transcription of chaperone proteins, increased protein degradation, and
typically reduced protein synthesis [106]. A causative link between ER stress and
autophagy induction has been established, but the exact molecular mechanisms have yet
to be elucidated [105,127]. One possible mechanism involves the release of calcium ions
from the ER triggered by ER stress: increased calcium concentration in the cytosol has
been associated with induction of autophagy [109,128,129]. Increased cytosolic calcium
also directly affects contraction by the SMC through activation of the myosin light chain
kinase. In fact, SM1 cells are more contractile due to increased phosphorylation of the
myosin light chain; they also have increased cytosolic calcium concentrations which are
reversed by treatment with an ER stress reliever. This is the first study which has linked
ER stress-induced calcium changes with alterations in muscle cell contractile function
(see model, Figure 4.12).
Previously described genetic triggers of TAAD are all predicted to decrease SMC
contractile function. The results showing increased contractility in the aortas and
cultured SMCs of SM1 transgenic mice are therefore confusing. All patients with
16p13.1 duplications have hypertension, so one possible explanation is that the
duplications are actually a genetic cause of hypertension due to increased SMC
contractility, and that the propensity towards high blood pressure drives the increased
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risk of aortic dissection. Alternatively, the SM1 model is imperfect as it only
overexpresses the SM1A isoform of myosin. Previous studies indicate that the SM1
myosin has a greater force generation capacity than SM2 myosin [31,32]. However,
there does not appear to be any change in the ratio of SM1:SM2 myosin in the aortic
tissue of SM1 transgenic mice [33]. The excessive activation of multiple metabolic
processes in SM1 cells could instead drive increased production of reactive oxygen
species; increased reactive oxygen species are associated with aortic disease [130,131].
Finally, and perhaps most plausibly the increased metabolic stress in SMCs
overexpressing myosin could leave the cells unable to respond to secondary stresses
such as increased biomechanical forces. A “second hit”, like hypertension, would
therefore dramatically affect the phenotype of myosin-overexpressing SMCs, most likely
leading to cell death and driving aortic pathology.
Although the use of the SM1 cell model has allowed for significant findings
about the role of increased myosin expression in regulating SMC phenotype, many
questions remain. A second model either linking SM1 transgene-induced phenotypic
changes to aortic disease in a live animal model or showing the same pathways activated
in SMCs derived from 16p13.1 duplication patients is necessary to confirm the findings
described in this study. However, these data support our hypothesis that rare variants in
the MYH11 gene affect SMC phenotype and contractility. Furthermore, if these results
are supported by future studies in additional models, these data suggest that small
molecule chemical chaperones, previously approved for treatment of urea cycle
disorders, may be useful to prevent disease in patients with 16p13.1 duplications
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[111,132]. As this is the single more common genetic alteration seen in TAAD patients,
a specific therapy to prevent aortic dissection would benefit a large patient population.
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Chapter 5: Discussion
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The focus of my work was broadly to determine how rare variants in MYH11
contribute to the pathogenesis of vascular diseases in humans. Two rare variants
associated with TAAD were selected for study: the most commonly identified
nonsynonymous missense variant, R247C, and duplications of the 16p13.1 locus
spanning the MYH11 gene. We hypothesized, based on genetic data linking these
variants with vascular disease, that each would alter the SMC phenotype and increase
risk of disease.
Based on genetic data gathered from patients, as well as the cellular and in vivo
data presented here, rare variants in MYH11 have the potential to predispose to multiple
distinct vascular pathologies, including vascular occlusive disease, aneurysm formation,
and aortic dissection.

SMC proliferation drives genetically triggered vascular occlusive disease
Vascular occlusive diseases like ischemic stroke and coronary artery disease are
typically associated with the formation of atherosclerotic plaques. Atherosclerosis occurs
due to accumulation of plasma-derived lipids in the vessel wall, followed by recruitment
of inflammatory cells including monocytes. Monocytes engulf the oxidized lipid plaques
within the wall to become foam cells. As the disease progresses, the plaque can become
complicated by cellular necrosis and thrombus formation, which in turn directly cause
cessation of blood flow [133]. However, another essential part of the disease process is
the production of cytokines and accumulation of reactive oxygen species in the wall that
alter the behavior of the smooth muscle cells in the medial layer and the fibroblasts in
the adventitia. In particular, SMCs undergo phenotypic switching to become
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proliferative and migratory, and they begin producing collagens and other extracellular
matrix proteins that contribute to fibrosis within the atherosclerotic plaque. In rare cases,
pathologists have noted the presence of plaque-like occlusions in arteries that lack lipid
accumulation. These lesions are called fibromuscular lesions, as they are populated
predominantly with muscle cells and their fibrotic output [134].
Due to the lethal nature of its complications, genetic contributors to
atherosclerosis have been heavily researched. The first genetic factors, and to date the
majority of genes, identified to increase risk of coronary artery disease and other
atherosclerosis-related vascular complications affect circulating lipid levels [135]. Genes
involved in endothelial integrity, oxidative stress, and thrombus formation have also
been implicated in increasing risk for atherosclerosis [136]. Notably, a role for genes
controlling SMC proliferation has not been extensively studied.
As mutations in ACTA2 were initially identified as a major cause of inherited
TAAD, the clinical histories of families carrying these mutations suggested a surprising
link between TAAD and early-onset vascular occlusive diseases such as ischemic stroke.
Several individuals with ACTA2 mutations also have a bilateral stroke syndrome called
Moyamoya disease. Moyamoya disease afflicts young patients with repeated strokes in
the terminal portion of the carotid artery at the base of the brain; patients are identified
by the characteristic formation of small collateral vessels around the occluded artery
apparent on contrast imaging [137,138]. Pathologic examination of the lesions in
Moyamoya patients reveals intimal occlusion by proliferating smooth muscle cells with
little lipid deposition and some inflammatory cell infiltration [139,140]. Moyamoya
disease runs in families and afflicts young patients, but although genetic mapping studies
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have identified multiple loci, causative genetic mutations have remained elusive [141143]. Although Moyamoya disease occurs among patients with some known genetic
syndromes, ACTA2 thus became the first gene associated with nonsyndromic inheritance
of Moyamoya disease [2].

Figure 5.1 Co-ocurrance of vascular occlusive disease with TAAD in ACTA2 and
MYH11 families. A) Pedigree of a family with ACTA2 mutation showing 50%
penetrance of TAAD with affected relatives developing premature stroke or coronary
artery disease (CAD). B) Pedigree of a family with MYH11 mutation similarly
showing stroke and CAD in mutation carriers or obligate carriers. Van Tran Fadulu et
al unpublished data, reprinted with permission.
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The same mutations in ACTA2 appeared to cause aneurysm formation in some
carriers and occlusive arterial lesions in others, although the pathogenic processes
driving the diseases seemed unrelated (Figure 5.1a). Occlusive lesions observed in
ACTA2 patients appeared similar to the Moyamoya lesions described above: they were
comprised of proliferating SMCs with little to no lipid deposition. SMCs explanted from
ACTA2 patients indeed proliferate more rapidly in culture, and further work using the
Acta2 knockout mouse model has elucidated a complex mechanism involving a number
of cancer-related pathways that drive hyperplasia of SMCs [62].
Although less abundant, there is genetic evidence to support a similar dual effect
of mutations in MYH11. Families with MYH11 mutations have affected members who
develop Moyamoya disease or coronary artery disease in addition to TAAD, although
the penetrance of occlusive vascular diseases is reduced compared with ACTA2 families
(Figure 5.1b). SMCs isolated from these patients are hyperplastic, similar to ACTA2
mutant SMCs [68]. As we began investigating rare variants in the MYH11 gene, we
therefore asked not only whether these variants might contribute to aneurysm formation
but also whether they might increase risk for occlusive diseases. The R247C rare variant
studied in this dissertation is found both in patients with TAAD and in patients with
occlusive disease. An in vivo model of vascular injury, the ligation of a single carotid
artery, did lead to an enhanced in vivo proliferative response in Myh11R247C/R247C mice,
and the cells explanted from the knockin mouse model proliferated more rapidly in
culture.
Unlike Acta2-/- cells, which completely lack actin and therefore do not have pools
of monomeric actin sequestering MRTF in the cytoplasm, the Myh11R247C/R247C SMCs
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were dedifferentiated via the canonical MRTF:SRF axis. Increased proliferation in these
cells was accompanied by decreased contractile gene and protein expression, loss of
actin polymerization, and the movement of MRTFA into the cytoplasm. We identified a
novel pathway linking altered force generation by the mutant myosin to this
dedifferentiated phenotype via loss of focal adhesion maturation and resultant decreases
in RhoA activation. However, dedifferentiation was not observed in Myh11R247C/R247C
SMCs within the intact aorta. Within the aortic wall, elastin fibers act as a natural brake
on SMC proliferation [144]. In addition, SMCs in developed, intact arteries are typically
quiescent and nonproliferative; stimuli downstream of vascular injury including release
of growth factors from reserves in the extracellular matrix, loss of contact inhibition at
the site of injury, and generation of reactive oxygen species induce a proliferative
phenotype in these cells [34]. We hypothesize that Myh11R247C/R247C SMCs are more
prone to dedifferentiation after injury and/or less responsive to signals to re-differentiate
than wild-type cells.
Our study therefore supports a role for MYH11 mutations in vascular occlusive
disease, and further suggests that any rare variant in the myosin head domain that affects
force generation may predispose carriers to vascular occlusive diseases via this same
pathway.

Decreased contractility and aneurysm formation
Early descriptive studies of the pathology of aortic aneurysms showed
fragmentation of elastin fibers and loss or dysfunction of supporting fibrils in the
extracellular matrix [145,146]. Loss of elastin integrity was predicted to drive aneurysm

104

formation as the ability of the vessel to resist biomechanical forces would be impaired,
leading to dilation and eventually rupture. The first genetic mutations identified to cause
aortic aneurysm were mutations in Fbn1 leading to Marfan syndrome, lending credence
to the hypothesis that defective structure or function of extracellular fibers underlies the
disease [147]. However, fibrillin-1, encoded by Fbn1, also plays a key role in
modulating growth factor signaling by sequestering the latent TGF- β complex within
the matrix [148]. Loss of functional fibrillin-1 would thus not only alter the response of
the aorta to biomechanical forces, but would also increase bioavailability of TGF-β
ligand. A mouse model of hypomorphic expression of Fbn1 suggested a critical role for
excessive TGF-β signaling in a pulmonary defect associated with Marfan syndrome
[149].
The potential role of TGF-β signaling in Marfan-associated aortic aneurysms was
first investigated in Fbn1 C1039G heterozygous knockin mice, which develop aortic
root aneurysms as early as two months of age. Pathology showed both increased
collagen expression and increased nuclear phosphorylated Smad2, suggesting that TGFβ signaling is increased in this model. Further, treatment of the mice with a TGF-β
neutralizing antibody partially attenuated aortic dilation and medial degeneration [54].
Mutations in TGFBR1 and TGFBR2 were identified to cause aortic disease, and
the role of TGF-β in aneurysm pathogenesis became controversial [56]. Despite
evidence of enhanced Smad signaling, as well as increased fibrotic signaling
downstream of TGF-β, in the aortic wall of patients with TGFBR2 mutations, the
mutations proved to encode kinase-deficient receptors leading to a loss of signaling
function [64]. SMCs explanted from the aortas of TGFBR2 patients were significantly
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less differentiated than control SMCs, showing decreased expression of all contractile
markers tested, as well as loss of contractile filament formation in vitro, both at baseline
and with exposure to TGF-β (Figure 5.2a). Similarly, immunohistochemical staining of
aortic sections from these patients showed a decrease of contractile protein signal in the
SMCs of the aortic medial layer in vivo (Figure 5.2b). Additionally, recently identified
mutations in TGFB2, encoding the ligand TGF-β2, are clearly loss-of-function mutations
resulting in haploinsufficiency for TGF-β2. Explanted SMCs from TGFB2 patients
clearly show reduced TGF-β2 protein; however levels of TGF-β2 are actually increased
in the disease aortic tissue, and there are further signs of excessive signaling activity in
vivo [58]. The role of TGF-β signaling in aortic disease remains controversial [150].
The most likely explanation is that TGF-β signaling becomes secondarily increased in
later stages of aortic disease, but the primary defect driving the disease in these patients
is related to the loss of TGF-β signaling.
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Figure 5.2 Loss of SMC differentiation with TGFBR2 mutations. A, B) Decreased
expression of contractile gene (A) and proteins (B) in SMCs explanted from patients with
TGFBR2 mutations. C, D) Immunohistochemistry on tissue from TGFBR2 patients shows
decreased signal for calponin (C) and SM-MHC (D). Reprinted with permission from
Oxford University Press [TGFBR2 mutations alter smooth muscle cell phenotype and
predispose to thoracic aortic aneurysms and dissections. Inamoto S, Kwartler CS, Lafont
AL, Liang YY, Fadulu VT, Duraisamy S, Willing M, Estrera A, Safi H, Hannibal MC,
Carey J, Wiktorowicz J, Tan FK, Feng XH, Pannu H, Milewicz DMM. Cardiovascular
Research. 2010]
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The discovery of mutations in the contractile genes ACTA2 and MYH11 around
the same time as evidence accumulated to support SMC dedifferentiation due to
TGFBR2 mutations suggested that loss of SMC contractility was potentially a universal
factor underlying all genetically triggered aortic disease [59,61]. The Fbn1 hypomorphic
mouse model also shows loss of aortic contractility and alterations in SMC phenotype,
confirming that these pathways are affected both by mutations in contractile protein
genes and genes encoding proteins involved in TGF-β signaling [48,151].
In this study, however, the R247C rare variant decreases aortic contractility but
does not induce spontaneous aortic disease. Therefore, these data indicate that decreased
contractility alone is insufficient to drive disease. Introducing the R247C variant into
another mouse model of contractile protein dysfunction, the Acta2-/- model, worsens
disease without worsening the contractile defect. Therefore, the relationship between
decreased contractility and development of aortic disease is nonlinear, but at the same
time, decreased contractility is the most direct result of the genetic lesions so it must
play some role in the disease process.
Recent studies investigating other pathways that might drive disease have shown
that signaling downstream of the angiotensin type I receptor (Agtr1) is responsible for
many of the pathologic changes accompanying aneurysm formation. A commonly used
model of aneurysm formation in the mouse is accomplished by infusion of angiotensinII, suggesting that angiotensin-related signaling alone is sufficient to drive aneurysm
formation [152]. Furthermore, the Agtr1 blocker, Losartan, has been used to successfully
prevent pathologic changes in a number of mouse models of aneurysm formation. The
most well-studied of these models is the Marfan Fbn1C1039G/+ mouse; aneurysm
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formation is accompanied by loss of aortic contractility, but also loss of elastin,
thickening of the medial layer, and evidence of increased TGF-β signaling, all of which
are prevented by treatment with losartan [54]. Our own lab has recently confirmed that
losartan similarly blocks many aspects of pathologic remodeling that accompany
increased biomechanical forces in the model of aneurysm development after transverse
aortic banding, and that losartan prevents aneurysm formation in Acta2-/- mice
(unpublished data).
Significantly, studies in both abdominal aneurysms and thoracic aneurysms have
shown a protective role for the angiotensin type II receptor (Agtr2). Knockout of the
receptor worsens aortic disease in the Marfan Fbn1C1039G/+ mouse, and pharmacologic
block of Agtr2 accelerates disease in the abdominal aorta after angiotensin II infusion
[153,154]. These same studies showed that treatment with losartan, an Agtr1-specific
blocker, but not with angiotensin converting enzyme inhibitors (ACE inhibitors)
ameliorates disease. ACE inhibitors may be ineffective treatments for aneurysm
progression because they block both the deleterious effects of Agtr1 and also the
protective effects of Agtr2. Alternatively, ACE inhibitors may be unable to prevent
disease because activation of Agtr1 is ligand-independent. Evidence of mechanical
stress-induced, ligand-independent activation of Agtr1 has been shown in
cardiomyocytes, and this activation can be blocked with specific blockers of Agtr1
[155,156]. If mechanical stretch can cause ligand-independent activation of Agtr1 in
smooth muscle cells, and if cells deficient in contractile function experience greater
mechanical stretch, this pathway could provide a link between mutations in the
contractile proteins and signaling known to drive aortic disease.
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Aortic dissection: the black box
A “typical” TAAD patient develops an aortic aneurysm that over time becomes
less stable and eventually progresses to dissection. However, careful examination of
families with TAAD indicates that some genetic mutations lead to stable aneurysm
formation with no history of dissection, and others lead to dissection with no evidence of
prior aortic enlargement [52]. Patients with mutations in MYH11 or MLCK tend to fall
into the latter category and dissect with little enlargement of the ascending aorta, as do
patients with 16p13.1 duplications [60,88]. Although aneurysm formation has been
extensively studied using mouse models, the molecular mechanisms that distinguish
aneurysm formation from aortic dissection have not been established.
There are two established mouse models of Marfan syndrome mentioned above:
the Fbn1C1039G/+ missense mutant mouse and the hypomorphic mouse Fbn1mgR/mgR. The
missense mutant mouse develops aneurysms that do not progress to dissection, while the
hypomorphic mouse progresses to dissection without aneurysm [157,158]. As described
above, aortic dilation and pathologic changes in the Fbn1C1039G/+ mouse can be blocked
by losartan. Similarly, treatment of the Fbn1mgR/mgR mouse with either a
metalloproteinase blocker, doxycycline, or with losartan prevents fragmentation of
elastin fibers and significantly delays death due to dissection [159,160]. Combinatorial
treatment with both doxycycline and losartan results in a synergistic effect on survival,
and in fact almost completely prevented deaths during through the length of the study
(Figure 5.3) [160]. These results tell us that elastin fragmentation may be critical for
preserving aortic integrity, as matrix metalloproteinases (MMPs) are extracellular
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proteases and elastin is one of their targets [50]. However, as both Marfan mouse models
have significant fragmentation of elastic fibers, these data do not inform us on the
differences in molecular events leading to stable aneurysms versus dissections.

Figure 5.3 Treatment with doxycycline, losartan, or a combination improves
survival in Fbn1mgR/mgR mice. Survival curve showing improvements in survival
with single treatment of Fbn1mgr/mgr mice with doxycycline or losartan, and
synergistic survival improments with combinatorial treatment. Reprinted with
permission from Wolters Kluwer Health. [MMP-2 Regulates Erk1/2
Phosphorylation and Aortic Dilatation inMarfan Syndrome. Xiong W, Meisinger T,
Knispel R, Worth JM, Baxter BT. Circulation Research. 2012.]
Unpublished in silico data using a sophisticated computer model to study the
effects of biomechanical forces on the aorta suggest a model whereby pools of
proteoglycans in the aortic wall may lead to disruption of the elastin fibers. As
proteoglycans accumulate and focally displace elastin, SMCs, and collagens, the tensile
strength of the wall decreases at that spot. Simultaneously, the discontinuity in the
patterning of elastin and cells in the wall locally increases wall stress. The combination
of decreased strength and increased stress could logically increase predisposition to
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rupture at that precise location. In the Acta2-/- Myh11R247C/R247C model, proteoglycan
deposition does appear to precede elastin fragmentation. However, there is no change in
survival and no signs of dissection in the Acta2-/- Myh11R247C/R247C mice out to one year
of age. An alternative hypothesis is that inflammatory cell infiltration underlies the
pathology of aortic dissection. Inflammation, particularly in the adventitia but also
extending into the medial layer, is common in the pathology of TAAD patients, however
its direct contribution to pathogenesis remains unclear [161].
Interestingly, while the addition of the R247C allele on the Acta2-/- background
does not induce dissections, preliminary data suggests that induction of hypertension in
Myh11R247C/R247C mice drives dissection without enlargement of the aorta. A combination
of L-NG-Nitroarginine methyl ester (L-NAME) in the drinking water and an 8% NaCl
diet increased average systolic blood pressure in Myh11R247C/R247C mice from 140mmHg
to 180mmHg, and this increase is sustained for at least three months. Three of thirteen
mice started on the hypertensive regimen died spontaneously during the four-month trial,
and upon dissection and fixation a fourth mouse was found to have a stable aortic
dissection. None of the thirteen Myh11R247C/R247C mice on the typical nonhypertensive
regimen died during the trial. Continued work on this model will begin to elucidate the
pathology associated with aneurysms versus dissections and determine if proteoglycan
deposition precedes dissection.
Hypertension is the most important risk factor driving aortic dissection, and all
patients with 16p13.1 duplications present with both hypertension and dissection.
Individuals with the duplications have an 11-fold increased risk of disease, and 1% of all
TAAD patients have the duplication, making this the most common genetic variant
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predisposing to TAAD identified to date. Because the duplication is a rare variant rather
than a Mendelian mutation, hypertension likely represents the “second hit” that leads to
disease in these patients.
The phenotypic data presented in Chapter 4 from the SM1 mouse establishes that
SMCs overexpressing myosin have a unique phenotype involving accelerated contractile
protein turnover. Furthermore, the pathway responsible for driving the protein turnover
is autophagic degradation downstream of ER stress. In addition to autophagy, ER stress
triggers calcium release from the ER, which leads to increased activity of myosin light
chain kinase and increased contractility of the SM1 cells. In vivo data from the SM1
transgenic mouse model also shows increased contractility of the aorta. SM1 myosin
generates more force than SM2 myosin, so it is possible the increased contractility is due
to a change in isoform expression. However, no change in the ratio of SM1:SM2
isoforms is observable on Western blots using lysates from the aortic tissue. Increased
contractility rather than decreased contractility has not previously been associated with
aortic disease; therefore, additional studies and a more complete disease model will be
required to establish the mechanism of disease downstream of protein turnover.
Currently, we are working with collaborators to generate patient-specific stem
cells from peripheral blood mononuclear cells collected from 16p13 duplication patients.
The goal would then be to transform those stem cells into smooth muscle cells and
validate the pathways identified in SM1 SMCs. An in vivo model would further help to
study the effects of increased biomechanical forces on myosin overexpressing SMCs
would help clarify the causative link between the cellular changes and the disease. One
possibility is that increased contractile function as well as the inefficient metabolic
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energy usage by the SM1 SMCs combines to generate significantly more reactive
oxygen species. Relevant to the role of angiotensin signaling in the etiology of TAAD,
reactive oxygen species have been shown to potentiate angiotensin-driven pathologic
processes in SMCs [162]. Alternatively, metabolic stress could uniquely predispose
these SMCs to contractile dysfunction in response to additional perturbations of the
system. Thus, while the cells appear more contractile under typical circumstances,
decreased contractility may still underlie the predisposition to disease.

Conclusion
The work presented in this dissertation establishes the importance of two
different rare variants in MYH11, the R247C missense mutation and chromosomal
duplication of the locus, in regulating SMC phenotype and increasing risk for vascular
diseases. Genomic duplications are a poorly understood cause of human disease, as the
mechanisms linking an extra copy of a gene to a disease process are not intuitively
obvious. The work presented here on the 16p13.1 duplications suggests a mechanism of
increased protein turnover that results from overexpression of a tightly regulated protein.
This novel mechanism may be more broadly applicable to other cases of disease-causing
genomic duplications.
The models established by this study provide a framework for future studies on
rare variants in vascular disease, and also provide strong preliminary evidence for the
mechanisms of vascular disease associated with these particular rare variants. Most
critically, the in vivo models involving Myh11R247C/R247C mice will allow us through
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future studies to examine the differences in pathology associated with stable aneurysm
formation versus dissection.
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